

Margaret (Peggy) Honein, Ph.D., M.P.H.

National Center on Birth Defects and Developmental Disabilities
Centers for Disease Control & Prevention
1600 Clifton Road, NE, Mailstop E-86
Atlanta, GA 30333

Telephone (office): (404) 498-3921
Email: MHonein@cdc.gov

EDUCATION

- 9/1989 – 6/1995 University of California, Los Angeles, California
Ph.D. (*Epidemiology*) 1995; M.P.H. (*Epidemiology*) 1992
- 9/1982 – 6/1986 University of California, Riverside, California
B.S. (*Biology*) 1986
- 2/1985 – 11/1985 University of California Education Abroad Program
University of Melbourne, Australia
-

WORK EXPERIENCE

- 3/2018 – present **Director, Division of Birth Defects and Infant Disorders [Title 42 Executive] (organizational name change from the Division of Congenital and Developmental Disorders on 10/1/19)**
- 9/2017 – 3/2018 **Acting Director, Division of Congenital and Developmental Disorders**
- National Center on Birth Defects and Developmental Disabilities (NCBDDD), Centers for Disease Control and Prevention, Atlanta, Georgia. Provides program management, oversight, and executive leadership to a Division of approximately 100 employees (full-time employees, FTEs) and nearly 100 contractors/fellows (non-FTE) staff. Annual appropriated budget of the Division is approximately \$73 million.
 - Responsible for allocation of human and financial resources, and determination of program areas for increased investment to reach critical public health goals.
 - Responsible for creating a vision and leading the scientific and programmatic activities of the Division including surveillance, research, and prevention of birth defects and infant disorders; surveillance and research on developmental disabilities including autism spectrum disorder (prior to October 2019 reorganization that re-aligned developmental disabilities work into the Division of Human Development and Disability); surveillance and research focused on lifespan issues for persons with congenital heart defects, spina bifida, and muscular dystrophy (latter two beginning in October 2019 following reorganization); and, key intervention and awareness programs to ensure all children have the opportunity to

reach their full potential. Responsible for direct supervision of Branch Chiefs, Chief Medical Officer, and Division Leads for management, policy, communications, strategy, and science.

- Responsible for developing and executing a scientific research agenda to advance key public health objectives.
- Represents the Division, Center, and CDC as a well-respected subject matter expert on birth defects and developmental disabilities at meetings with both federal and non-federal partners. Develops and maintains key relationships with stakeholders including public health and clinical partners as well as leadership of state and local health departments.
- Represents CDC in briefing congressional staffers on selected topics including congenital heart defects, surveillance of emerging threats to mothers and babies (including the impact of Zika virus infection in pregnancy), and neonatal abstinence syndrome.

1/2016 – 9/2017

Co-lead, Pregnancy and Birth Defects Task Force, CDC Zika Response

- Emergency Operations Center, Centers for Disease Control and Prevention
- Responsible for developing an agenda for surveillance and research providing critical subject matter expertise and leading plans to rapidly understand the association between Zika virus infection during pregnancy and adverse outcomes including serious birth defects.
- Responsible for leading rapid development of clinical guidance related to Zika virus infections, in collaboration with key stakeholders including state and local health departments and public health and clinical organizations; this ensured public health data was rapidly used to improve clinical care.
- Responsible for successfully establishing extensive domestic and international collaborations and rapidly implementing short and long-term projects to better understand the impact of Zika virus infection during pregnancy. Led establishment of a Memorandum of Understanding with the National Health Institute in Colombia that was signed by the CDC Director in 2016.
- Co-led (with Division of Vector-borne Diseases) regular congressional staffer briefings (by phone) during the response.
- Responsible for recruiting and managing large task force of approximately 100 full-time staff deployed to the Emergency Operations Center to address critical issues related to pregnancy and birth defects, and managing a budget of approximately \$135 million in Fiscal Years 2016 and 2017. Led development and execution of budget for this emergency response to protect pregnant women and infants. Rapidly established as a leading subject matter expert on the impact of Zika virus infection during pregnancy.
- Directly reported out on key progress throughout the emergency response to the Center Director of the National Center on Birth Defects and

Developmental Disabilities, the Incident Manager for the CDC Zika Response, and the CDC Director.

12/2010- 9/2017 **Branch Chief (Distinguished Consultant, Title 42)**

10/2006 – 12/2010 **Branch Chief (Supervisory Health Scientist, GS-15)**

- Birth Defects Branch, Division of Congenital and Developmental Disorders, National Center on Birth Defects and Developmental Disabilities (NCBDDD), Centers for Disease Control and Prevention, Atlanta, Georgia. Branch includes approximately 35 employees (FTEs) and 40 contractors/fellows (non-FTE) staff.
- Directed strategic planning of the Branch to develop and achieve key priorities each year; developed and updated a research agenda to direct efforts to those studies with the greatest potential for public health impact.
- Supervised and mentored staff to ensure scientists are developing professionally and achieving and maintaining a high level of productivity.
- Managed a budget of over \$20 million in federal appropriations for the Birth Defects Branch.
- Developed and maintained strong partnerships with key stakeholders in birth defects and public health.
- Developed plans and priorities for new CDC funding to support congenital heart defects work focused on adolescents and adults, including a convening of experts in September 2012; initial funding received in FY2012, and expanded to nearly \$4 million in FY2015.
- Provided accurate and thorough oral and written responses to congressional staffers in response to inquiries.
- Conducted and published independent epidemiological research to advance the understanding of the causes of and important risk factors for major birth defects.
- Provided senior leadership and oversight to both domestic and international cooperative agreements.
- Represented Division and Center on both CDC and external committees. Examples include: serving as a consult and ad-hoc member for FDA committee's reviewing products with possible risk management concerns related to exposure during pregnancy (2006-present); serving as a member of an advisory committee for a new medication (Letairis) to evaluate the safety or risk based on post-marketing data (2008-9); serving as the Epidemiology Lead for the Maternal Health Team in the pandemic influenza response (2009-10); serving as Chair of the Vaccines and Medications in Pregnancy Surveillance System advisory committee (2010-present), an effort funded by the Biomedical Advanced Research and Development Authority and the Agency for Healthcare Research and Quality; serving as the Atlanta-based lead on the Ohio Ebola contact tracing investigation (2014).
- Served as an expert peer reviewer for numerous key scientific journals including: New England Journal of Medicine; JAMA; Pediatrics; Circulation; Birth Defects Research Part A: Clinical and Molecular

Teratology; American Journal of Epidemiology; Drug Safety; American Journal of Medical Genetics; Epidemiology; Journal of Women's Health; Social Science and Medicine; Preventive Medicine; International Journal of Environmental Research and Public Health; Women's Health Issues.

- In December 2010, credentialed as a Distinguished Consultant by CDC's Compensation and Pay Review Sub-Committee for Title 42 Executives. Credentialing is based on nominations for scientists at the top of the Title 5 pay grade, and criteria are public health impact, scientific leadership, scientific service, collaborations and partnerships, and administrative responsibilities

11/04 – 2/06

- **Acting Team Leader**, Birth Defects State Research Partnerships Team, National Center on Birth Defects and Developmental Disabilities (NCBDDD), Centers for Disease Control and Prevention, Atlanta, Georgia.
- Served as team lead for a team of 5-8 employees (FTEs), 8 contractors, and 2 fellows/interns. Managed budget of approximately \$14 million including cooperative agreements and intramural projects.

7/99 – 10/06

- **Epidemiologist**, National Center on Birth Defects and Developmental Disabilities (NCBDDD), Centers for Disease Control and Prevention, Atlanta, Georgia.
- Served as the Principal Investigator for the Atlanta site of the National Birth Defects Prevention Study (NBDPS) and the lead epidemiologist for the multi-site NBDPS study from 2001-2006. Served as the project officer from 2004 to the 2006 for the eight states funded to conduct the NBDPS.
- Served as a CDC representative on the NBDPS data sharing committee, questionnaire/methods committee, coding committee, and cleft working group --- critical committees to the function of the National Birth Defects Prevention Study. Provided oversight to CDC staff and contractors working on the NBDPS.
- Provided leadership to a multi-site Epi-Aid investigation of bacterial meningitis in children with cochlear implants in 2002-2003.
- Conducted and published original epidemiological research on risk factors for birth defects and methods of birth defects research.
- Served as a primary supervisor for an EIS officer from 2001-2003, and a secondary supervisor for an EIS officer from 2005 – 2007. Supervised project with 2001 EIS officer that was awarded the Langmuir Prize for the outstanding EIS manuscript and the Charles C. Shepard Award.
- Served as an expert peer reviewer for scientific journals including: New England Journal of Medicine; JAMA; Birth Defects Research Part A: Clinical and Molecular Teratology; American Journal of Epidemiology; Drug Safety; The Medical Journal of Australia.
- Represented the center on numerous projects including: the Antiretroviral Pregnancy Registry, a drug registry sponsored by multiple pharmaceutical

companies to monitor the effects of antiretroviral medicals when used during pregnancy to better establish the safety or risk of specific medications; a CDC led a convening of experts in January 2006 to prioritize a research agenda for orofacial clefts; convened stakeholders in June 2006 to develop a prioritized public health research agenda for craniosynostosis; and, a workshop/meeting of experts on a public health approach to monitoring drug exposures during pregnancy.

7/97 – 6/99

- **Epidemic Intelligence Service (EIS)**, Centers for Disease Control and Prevention, Atlanta, Georgia. Based in the Division of Birth Defects & Pediatric Genetics, National Center for Environmental Health (NCEH).
 - Led two field investigations: 1) investigation of the continued occurrence of pregnancies exposed to Accutane (isotretinoin) in California, and 2) investigation of infantile hypertrophic pyloric stenosis after use of erythromycin for pertussis prophylaxis (manuscript awarded Langmuir Prize).
 - Contributed to numerous division projects, and published 7 peer-reviewed manuscripts based on work undertaken during the EIS fellowship.
-

PEER-REVIEWED PUBLICATIONS

1. Gray GC, Rodier GR, Matras-Maslin VC, **Honein MA**, Ismail EA, Botros BA, Soliman AK, Merrell BR, Wang SP, and Grayston JT. Serologic evidence of respiratory and rickettsial infection among Somali refugees. *American Journal of Tropical Medicine and Hygiene*, 1995; **52**(4):349-353.
2. **Honein MA**, Paulozzi LJ. Birth defects surveillance: assessing the “gold standard”. *American Journal of Public Health*, 1999; **89**: 1238-40.
3. **Honein MA**, Paulozzi LJ, Cragan JD, Correa A. Evaluation of selected characteristics of pregnancy drug registries. *Teratology*, 1999;**60**:356-64.
4. **Honein MA**, Paulozzi LJ, Himelright IM, Lee B, Cragan JD, Patterson L, Correa A, Hall S, Erickson JD. Infantile hypertrophic pyloric stenosis after pertussis prophylaxis with erythromycin: a case review and cohort study. *Lancet*, 1999; **354**:2101-5.
5. **Honein MA**, Paulozzi LJ, and Moore CA. Family history, maternal smoking, and clubfoot: an indication of a gene-environment interaction. *American Journal of Epidemiology*, 2000;**152**:658-665.
6. **Honein MA**, Paulozzi LJ, Mathews TJ, Erickson JD, Wong LY. Impact of folic acid fortification of the US food supply on the occurrence of neural tube defects. *Journal of the American Medical Association (JAMA)*, 2001; **285**:2981-2986.

7. **Honein MA**, Paulozzi LJ, Erickson JD. Continued occurrence of Accutane®-exposed pregnancies. *Teratology*, 2001; 64:142-147.
8. **Honein MA**, Paulozzi LJ, Watkins ML. Maternal smoking and birth defects: validity of birth certificate data for effect estimation. *Public Health Reports*, 2001;116:327-335.
9. Brown AS, Fernhoff PM, Waisbren SE, Frazier DM, Singh R, Rohr F, Morris JM, Kenneson A, MacDonald P, Gwinn M, **Honein M**, Rasmussen SA. Barriers to successful dietary control among pregnant women with phenylketonuria. *Genetics in Medicine*, 2002;4(2):84-89.
10. Williams LJ, **Honein MA**, Rasmussen SA. Methods for a public health response to birth defects clusters. *Teratology*, 2002; 66:S50-S58.
11. Reefhuis J, **Honein MA**, Shaw GM, Romitti PA. Fertility treatments and craniosynostosis: California, Georgia, and Iowa, 1993-1997. *Pediatrics*, 2003; 111:1163-1166.
12. Daniel KL, **Honein MA**, Moore CA. Sharing prescription medication among teenage girls: potential danger to unplanned/undiagnosed pregnancies. *Pediatrics*, 2003; 111:1167-1170.
13. Watkins ML, Rasmussen SA, **Honein MA**, Botto LD, Moore CA. Maternal obesity and the risk for birth defects. *Pediatrics*, 2003; 111:1152-1158.
14. Reefhuis J, **Honein MA**, Whitney CG, Chamany S, Mann EA, Biernath K, Broder K, Manning S, Avashia S, Victor M, Costa P, Devine O, Graham A, Boyle C. Risk of bacterial meningitis in children with cochlear implants. *New England Journal of Medicine*, 2003; 349:435-445.
15. **Honein MA**, Moore CA, Watkins ML. Subfertility and prepregnancy overweight/obesity: possible interaction between these risk factors in the etiology of congenital renal anomalies. *Birth Defects Research Part A: Clinical and Molecular Teratology*, 2003; 67:572-577.
16. Abe K, **Honein MA**, Moore CA. Maternal febrile illnesses, medication use, and the risk of congenital renal anomalies. *Birth Defects Research Part A: Clinical and Molecular Teratology*, 2003; 67:911-918.
17. Reefhuis J, **Honein MA**. Maternal age and non-chromosomal birth defects, Atlanta 1968-2000: teenager or thirty-something, who is at risk? *Birth Defects Research Part A: Clinical and Molecular Teratology*, 2004; 70:572-579.
18. **Honein MA**, Moore CA, Erickson JD. Can we ensure the safe use of known teratogens: Introduction of generic isotretinoin in the US as an example. *Drug Safety*, 2004; 27:1069-80.

19. Than L, **Honein MA**, Watkins ML, Yoon PW, Daniel KL, Correa A. Intent to become pregnant as a predictor of exposures during pregnancy: is there a relation? *Journal of Reproductive Medicine*, 2005; 50(6):389-396.
20. Yuskiv N, **Honein MA**, Moore CA. Reported multivitamin consumption and the occurrence of multiple congenital anomalies. *American Journal of Medical Genetics Part A*, 2005; 136:1-7.
21. Werler MM, Mitchell AA, Hernandez-Diaz S, **Honein MA**, and the National Birth Defects Prevention Study. Use of over-the-counter medications during pregnancy. *American Journal of Obstetrics and Gynecology*, 2005; 193:771-7.
22. Crider KS, Reefhuis J, Woomert A, **Honein MA**. Racial and ethnic disparity in DNA collection at the Atlanta site of the National Birth Defects Prevention Study. *American Journal of Epidemiology*, 2006;164:805-12.
23. Yang Q, Chen H, Correa A, Devine O, Mathews TJ, **Honein MA**. Racial differences in infant mortality attributable to birth defects in the United States, 1989-2002. *Birth Defects Research Part A: Clinical and Molecular Teratology*, 2006; 76:706-13.
24. Canfield MA, **Honein MA**, Yuskiv N, Xing J, Mai CT, Collins JS, Devine O, Petrini J, Ramadhani TA, Hobbs CA, Kirby RS. National estimates and race/ethnic-specific variation of selected birth defects in the United States, 1999-2001. *Birth Defects Research Part A: Clinical and Molecular Teratology*, 2006;76:747-56.
25. Yazdy MM, **Honein MA**, Xing J. Reduction in orofacial clefts following folic acid fortification of the U.S. grain supply. *Birth Defects Research Part A: Clinical and Molecular Teratology*, 2007; 79:16-23.
26. **Honein MA**, Rasmussen SA, Reefhuis J, Romitti PA, Lammer EJ, Sun L, and Correa A. Maternal smoking and environmental tobacco smoke, and the risk of orofacial clefts. *Epidemiology*. 2007;18:226-233.
27. Yazdy MM, **Honein MA**, Rasmussen SA, Frias JL. Priorities for future public health research in orofacial clefts. *Cleft Palate Craniofacial Journal*, 2007;44:351-357.
28. Rasmussen SA, Yazdy MM, Carmichael SL, Jamieson DJ, Canfield MA, **Honein MA**; for the National Birth Defects Prevention Study. Maternal thyroid disease as a risk factor for craniosynostosis. *Obstetrics and Gynecology*, 2007;110:369-377.
29. Romitti PA, Sun L, **Honein MA**, Reefhuis J, Correa A, Rasmussen SA. Maternal periconceptional alcohol consumption and risk of orofacial clefts. *American Journal of Epidemiology*, 2007; 166: 775-785.

30. The NS, **Honein MA**, Caton AR, Moore CA, Siega-Riz AM, Druschel CM, and The National Birth Defects Prevention Study. Risk factors for isolated biliary atresia, National Birth Defects Prevention Study, 1997-2002. *American Journal of Medical Genetics Part A*, 2007; 143A:2274-2284.
31. Bitsko RH, Reefhuis J, Romitti PA, Moore CA, **Honein MA**. Periconceptional consumption of vitamins containing folic acid and risk for multiple congenital anomalies. *American Journal of Medical Genetics Part A*, 2007; 143A:2397-2405.
32. **Honein MA**, Lindstrom JA, Kweder SL. Can we ensure the safe use of known human teratogens?: The iPLEDGE test case. *Drug Safety*, 2007; 30(1):5-15. Review.
33. Rasmussen SA, Yazdy MM, Frias JL, **Honein MA**. Priorities for public health research in craniosynostosis: summary and recommendations from a Centers for Disease Control and Prevention-sponsored meeting. *American Journal of Medical Genetics Part A*, 2008; 146A:149-58.
34. Carmichael SL, Ma C, Rasmussen SA, **Honein MA**, Lammer EJ, Shaw GM, and the National Birth Defects Prevention Study. Craniosynostosis and maternal smoking. *Birth Defects Research Part A: Clinical and Molecular Teratology*, 2008;82:78-85.
35. Jenkins MM, Rasmussen SA, Moore CA, **Honein MA**. Ethical issues raised by incorporation of genetics into the National Birth Defects Prevention Study. *American Journal of Medical Genetics Part C: Seminars in Medical Genetics*, 2008;148C:40-46.
36. Yazdy MM, Autry AR, **Honein MA**, Frias JL. Use of special education services by children with orofacial clefts. *Birth Defects Research Part A: Clinical and Molecular Teratology*, 2008;82:147-54.
37. Boulet SL, Rasmussen SA, **Honein MA**. A population-based study of craniosynostosis in metropolitan Atlanta, 1989-2003. *American Journal of Medical Genetics Part A*, 2008;146A:984-991.
38. Malik S, Cleves MA, **Honein MA**, Romitti PA, Botto LD, Yang S, Hobbs CA, and the National Birth Defects Prevention Study. Maternal smoking and congenital heart defects. *Pediatrics*. 2008;121:e810-816.
39. Bitsko RH, Reefhuis J, Louik C, Werler M, Feldkamp ML, Waller DK, Frias J, **Honein MA**, and the National Birth Defects Prevention Study. Periconceptional use of weight loss products including ephedra and the association with birth defects. *Birth Defects Research Part A: Clinical and Molecular Teratology*, 2008; 82:553-562.
40. Boulet SL, Molinari NA, Grosse SD, **Honein MA**, Correa-Villaseñor A. Health care expenditures for infants and young children with Down syndrome in a privately insured population. *Journal of Pediatrics*, 2008;153:241-246.

41. Petersen EE, Rasmussen SA, Lyon Daniel K, Yazdy MM, **Honein MA**. Prescription medication borrowing and sharing among women of reproductive age. *Journal of Women's Health*, 2008;17:1073-1080.
42. Slickers JE, Olshan AF, Siega-Riz AM, **Honein MA**, Aylsworth AS; National Birth Defects Prevention Study. Maternal body mass index and lifestyle exposures and the risk of bilateral renal agenesis or hypoplasia: the national birth defects prevention study. *American Journal of Epidemiology*, 2008;168:1259-67.
43. MacLehose RF, Olshan AF, Herring AH, **Honein MA**, Shaw GM, Romitti PA and the National Birth Defects Prevention Study. Bayesian methods for correcting misclassification: an example from birth defects epidemiology. *Epidemiology*, 2009;20:27-35.
44. Miller EA, Manning SE, Rasmussen SA, Reefhuis J, **Honein MA**, and the National Birth Defects Prevention Study. Maternal exposure to tobacco smoke, alcohol and caffeine, and risk of anorectal atresia: National Birth Defects Prevention Study 1997-2003. *Paediatric and Perinatal Epidemiology*, 2009;23:9-17.
45. Reefhuis J, **Honein MA**, Schieve LA, Correa A, Hobbs CA, Rasmussen SA, and the National Birth Defects Prevention Study. Assisted reproductive technology and major structural birth defects in the United States. *Human Reproduction*, 2009;24:360-6.
46. **Honein MA**, Kirby RS, Meyer RE, Xing J, Skerrette NI, Yuskiv N, Marengo L, Petrini JR, Davidoff MJ, Mai CT, Druschel CM, Viner-Brown S, and Sever LE for the National Birth Defects Prevention Network. The association between major birth defects and preterm birth. *Maternal and Child Health Journal*, 2009;13(2):164-175.
47. Collier SA, Rasmussen SA, Feldkamp ML, **Honein MA**; National Birth Defects Prevention Study. Prevalence of self-reported infection during pregnancy among control mothers in the National Birth Defects Prevention Study. *Birth Defects Research Part A: Clinical and Molecular Teratology*, 2009; 85:193-201.
48. Genisca AE, Frias JL, Broussard C, **Honein MA**, Lammer EJ, Moore CA, Shaw GM, Murray JC, Yang W, Rasmussen SA, and the National Birth Defects Prevention Study. Orofacial clefts in the National Birth Defects Prevention Study, 1997-2004. *American Journal of Medical Genetics Part A*. 2009;149A:1149-58.
49. Boulet SL, Grosse SD, **Honein MA**, Correa-Villasenor A. Children with orofacial clefts: health-care use and costs among a privately insured population. *Public Health Reports*, 2009;124:447-53.
50. Johnson CY, **Honein MA**, Hobbs CA, Rasmussen SA, and the National Birth Defects Prevention Study. Prenatal diagnosis of orofacial clefts, National Birth Defects Prevention Study, 1998-2004. *Prenatal Diagnosis*. 2009;29(9):833-9.

51. Werler MM, Mitchell AA, Moore CA, **Honein MA** and the National Birth Defects Prevention Study. Is there epidemiologic evidence to support vascular disruption as a pathogenesis of gastroschisis? *American Journal of Medical Genetics*, 2009;149A:1399-406.
52. Collier SA, Browne ML, Rasmussen SA, **Honein MA**, and the National Birth Defects Prevention Study. Maternal caffeine intake during pregnancy and orofacial clefts. *Birth Defects Research Part A: Clinical and Molecular Teratology*, 2009;85:842-9.
53. Jamieson DJ, **Honein MA**, Rasmussen SA, Williams JL, Swerdlow DL, Biggerstaff MS, Lindstrom S, Louie JK, Christ CM, Bohm SR, Fonseca VP, Ritger KA, Kuhles DJ, Eggers P, Bruce H, Davidson HA, Lutterloh E, Harris ML, Burke C, Cocoros N, Finelli L, MacFarlane KF, Shu B, Olsen SJ, Novel Influenza A (H1N1) Pregnancy Working Group. H1N1 2009 influenza virus infection during pregnancy in the USA. *Lancet*. 2009; 374:451-8.
54. Jenkins MM, Reed-Gross E, Rasmussen SA, Barfield WD, Prue CE, Gallagher ML, **Honein MA**. Maternal attitudes toward DNA collection for gene-environment studies: a qualitative research study. *American Journal of Medical Genetics Part A*, 2009; 149A:2378–2386.
55. Louie JK, Acosta M, Jamieson DJ, **Honein MA**; California Pandemic (H1N1) Working Group. Severe 2009 H1N1 influenza in pregnant and postpartum women in California. *New England Journal of Medicine* 2010;362:27-35.
56. Miller EA, Rasmussen SA, Siega-Riz AM, Frias J, **Honein MA**, and the National Birth Defects Prevention Study. Risk factors for non-syndromic holoprosencephaly in the National Birth Defects Prevention Study. *American Journal of Medical Genetics Part C: Seminars in Medical Genetics*, 2010;154C:62-72.
57. Creanga AA, Johnson T, Graitcer S, Hartman L, Al-Samarrai T, Schwarz AG, Chu SY, Sackoff J, Jamieson DJ, Fine AD, Shapiro-Mendoza CK, Jones LE, Uyeki TM, Balter S, Bish CL, Finelli L, **Honein MA**. Severity of 2009 Pandemic Influenza A (H1N1) Virus Infection in Pregnant Women. *Obstetrics & Gynecology*. 2010 ;115:717-726.
58. Broussard C, Louik C, Mitchell AA, and **Honein MA**, and the National Birth Defects Prevention Study. Herbal use before and during pregnancy. *American Journal of Obstetrics and Gynecology*, 2010; 202(5):443.e1-6.
59. Duwe KN, Reefhuis J, **Honein MA**, Schieve LA, Rasmussen SA, and the National Birth Defects Prevention Study. Epidemiology of fertility treatment use among women with liveborn infants, 1997-2004. *Journal of Women's Health*, 2010;19(3):407-16.
60. Prakalapakorn SG, Rasmussen SA, Lambert SR, **Honein MA**, and the National Birth Defects Prevention Study. Assessment of risk factors for infantile cataracts using

a case-control study, National Birth Defects Prevention Study, 2000–2004. *Ophthalmology*, 2010;117(8):1500-5.

61. Siston AM, Rasmussen SA, **Honein MA**, Fry A, et al. Pandemic 2009 Influenza A(H1N1) Virus Illness among Pregnant Women in the United States. *JAMA*, 2010;303(15):1517-1525.

62. Boulet SL, Rasmussen SA, **Honein MA**; National Birth Defects Prevention Study. Maternal body mass index as a risk factor for craniosynostosis. *American Journal of Medical Genetics Part A*, 2010;152A(11):2895-7.

63. Reefhuis J, **Honein MA**, Schieve LA, Rasmussen SA; the National Birth Defects Prevention Study. Use of clomiphene citrate and birth defects, National Birth Defects Prevention Study, 1997-2005. *Human Reproduction*, 2011;26(2):451-457.

64. Mei JV, Lia LX, Rasmussen SA, Collier S, Frias JL, **Honein MA**, Shaw GM, Lorey F, Meyer R, Chaing S, Canfield MA, Jones J, Hannon WH. Effect of specimen storage conditions on newborn dried blood spots used to assess *Toxoplasma gondii* Immunoglobulin M (IgM). *Clinica Chimica Acta*, 2011;412:455-459.

65. Broussard CS, Rasmussen SA, Reefhuis J, Friedman JM, Jann MW, Riehle-Colarusso T, **Honein MA**; National Birth Defects Prevention Study. Maternal treatment with opioid analgesics and risk for birth defects, *American Journal of Obstetrics and Gynecology*, 2011 Apr;204(4):314.e1-11.

66. Gallagher ML, Sturchio C, Smith A, Koontz D, Jenkins MM, **Honein MA**, Rasmussen SA. Evaluation of mailed pediatric buccal cytobrushes for use in a case-control study of birth defects. *Birth Defects Research Part A: Clinical and Molecular Teratology*, 2011;91(7):642-8.

67. Creanga AA, Kamimoto L, Newsome K, D'mello T, Jamieson DJ, Zotti ME, Arnold KE, Baumbach J, Bennett NM, Farley MM, Gershman K, Kirschke D, Lynfield R, Meek J, Morin C, Reingold A, Ryan P, Schaffner W, Thomas A, Zansky S, Finelli L, **Honein MA**. Seasonal and 2009 pandemic influenza A (H1N1) virus infection during pregnancy: a population-based study of hospitalized cases. *American Journal of Obstetrics and Gynecology*, 2011;204(6 Suppl 1):S38-45.

68. Gilboa SM, Broussard CS, Devine OJ, Duwe KN, Flak AL, Boulet SL, Moore CA, Werler MM, **Honein MA**. Influencing clinical practice regarding the use of antiepileptic medications during pregnancy: Modeling the potential impact effects on the prevalences of spina bifida and cleft palate in the United States. *American Journal of Medical Genetics Part C Seminars in Medical Genetics*, 2011;157(3):234-46.

69. Jenkins MM, Reed-Gross E, Barfield WD, Prue CE, Gallagher ML, Rasmussen SA, **Honein MA**. Qualitative assessment of study materials and communication strategies

used in studies that include DNA collection. *American Journal of Medical Genetics Part A*. 2011;155A(11):2721-31.

70. Broussard CS, Gilboa SM, Lee KA, Oster M, Petrini JR, **Honein MA**. Racial/Ethnic Differences in Infant Mortality Attributable to Birth Defects by Gestational Age. *Pediatrics* 2012;130(3):e518-27.

71. Johnson CY, **Honein MA**, Flanders WD, Howards PP, Oakley GP, Rasmussen SA. Pregnancy termination following prenatal diagnosis of anencephaly or spina bifida: a systematic review of the literature. *Birth Defects Research Part A: Clinical and Molecular Teratology*, 2012 Nov;94(11):857-63.

72. Peters SL, Lind JN, Humphrey JR, Friedman JM, **Honein MA**, Tassinari MS, Moore CA, Mathis LL, Broussard CS. Safe lists for medications in pregnancy: inadequate evidence base and inconsistent guidance from Web-based information, 2011. *Pharmacoepidemiology and Drug Safety*, 2013;22(3):324-8.

73. Oster ME, Lee KA, **Honein MA**, Colarusso T, Shin M, Correa A. Trends in and prognostic factors for survival for infants with critical congenital heart defects: Atlanta, Georgia, 1979-2005. *Pediatrics*, 2013;131(5):e1502-8.

74. Lind JN, Tinker SC, Broussard CS, Reefhuis J, Carmichael SL, **Honein MA**, Olney RS, Parker SE, Werler MM, and the National Birth Defects Prevention Study. Maternal medication and herbal use and risk for hypospadias: Data from the National Birth Defects Prevention Study, 1997—2007. *Pharmacoepidemiology and Drug Safety*, 2013;22(7):783-93.

75. Simeone RM, Rasmussen SA, Mei JV, Dollard SC, Frias JL, Shaw GM, Canfield MA, Meyer R, Chaing S, Jones J, Lorey F, **Honein MA**. A pilot study using newborn dried blood spots to assess the contributions of cytomegalovirus and *Toxoplasma gondii* to the etiology of congenital hydrocephalus. *Birth Defects Research Part A: Clinical and Molecular Teratology*, 2013;97(7):431-6.

76. **Honein MA**, Devine O, Sharma AJ, Rasmussen SA, Park S, Kucik JE, Boyle C. Modeling the potential public health impact of prepregnancy obesity on adverse fetal and infant outcomes. *Obesity*, 2013;21(6):1276-1283.

77. Thorpe PG, Gilboa SM, Hernandez-Diaz S, Lind J, Cragan JD, Briggs G, Kweder S, Mathis L, Friedman JM, Mitchell AA, **Honein MA**. Use of medications in the first trimester of pregnancy: most common exposures and critical gaps in understanding fetal risk. *Pharmacoepidemiology and Drug Safety*, 2013;22(9):1013-8.

78. Oster ME, Riehle-Colarusso T, Simeone RM, Gurvitz M, Kaltman JR, McConnell M, Rosenthal GL, **Honein MA**. A public health science agenda for congenital heart defects: Report from a Centers for Disease Control and Prevention experts meeting. *Journal of the American Heart Association*, 2013;2(5):e000256.

79. Tinker SC, Devine O, Mai C, Hamner H, Reefhuis J, Gilboa S, Dowling N, **Honein MA**. Preventing neural tube defects: estimating the potential impact from folic acid fortification of corn masa flour. *Birth Defects Research Part A: Clinical and Molecular Teratology*, 2013;97:649–657.
80. Ailes EC, Gilboa SM, Riehle-Colarusso T, Johnson CY, Hobbs CA, Correa A, **Honein MA** and the National Birth Defects Prevention Study. Prenatal diagnosis of non-syndromic congenital heart defects. *Prenatal Diagnosis*, 2014;34(3):214-22.
81. Ailes EC, Newsome K, Williams JL, McIntyre AF, Jamieson DJ, Finelli L, **Honein MA**. CDC Pregnancy Flu Line: Monitoring severe illness among pregnant women with influenza. *Maternal and Child Health Journal*, 2014;18(7):1578-82.
82. Jenkins MM, Reefhuis J, Gallagher ML, Mulle JG, Hoffmann T, Koontz DA, Sturchio C, Rasmussen SA, Witte JS, Richter P, Lammer EJ, **Honein MA**. Maternal smoking, select xenobiotic metabolizing enzyme gene variants, and gastroschisis risk. *American Journal of Medical Genetics*, 2014;164A(6):1454-63.
83. **Honein MA**, Devine O, Grosse SD, Reefhuis J. Prevention of orofacial clefts caused by smoking: implications of the Surgeon General’s Report. *Birth Defects Research Part A: Clinical and Molecular Teratology*, 2014;100(11):822-5.
84. Broussard CS, Frey MT, Hernandez-Diaz S, Greene MF, Chambers CD, Sahin L, Collins Sharp BA, **Honein MA**. Considerations for a Task Force approach to evaluate the embryonic, fetal, and maternal effects of medication treatment during pregnancy: Summary of a Centers for Disease Control and Prevention-convened meeting. *American Journal of Obstetrics and Gynecology*, 2014;211(3):208-214.
85. Johnson CY, Flanders WD, Strickland MJ, **Honein MA**, Howards PP. Potential sensitivity of bias analysis results to incorrect assumptions of nondifferential or differential binary exposure misclassification. *Epidemiology*, 2014;25(6):902-9.
86. Gilboa SM, Ailes EC, Rai RP, Anderson JA, **Honein MA**. Antihistamines and birth defects: a systematic review of the literature. *Expert Opinion on Drug Safety*, 2014;13(12):1667-98.
87. Simeone RM, Oster ME, Cassell CH, Armour BS, Gray DT, **Honein MA**. Pediatric hospital resource use for congenital heart defects. *Birth Defects Research Part A: Clinical and Molecular Teratology*, 2014;100(12):934-43.
88. Polen KN, Sandhu PK, **Honein MA**, Green KK, Berkowitz JM, Pace J, Rasmussen SA. Knowledge and attitudes of adults towards smoking in pregnancy: Results from the HealthStyles© 2008 Survey. *Maternal and Child Health Journal*, 2015;19(1):144-54.

89. Simeone RM, Devine OJ, Marcinkevage JA, Gilboa SM, Razzaghi H, Bardenheier B, Sharma AJ, **Honein MA**. Diabetes and congenital heart defects: a systematic review, meta-analysis, and modeling project. *American Journal of Preventive Medicine*, 2015 Feb;48(2):195-204.
90. Howards PP, Johnson CY, **Honein MA**, Flanders WD, and the National Birth Defects Prevention Study. Adjusting for bias due to incomplete case ascertainment in case-control studies of birth defects. *American Journal of Epidemiology*, 2015;181(8):595-607.
91. Ailes EC, Gilboa SM, **Honein MA**, Oster ME. The potential impact and limitations of screening for critical congenital heart defects through pulse oximetry. *Pediatrics*, 2015;135(6):1000-8.
92. Simeone RM, Oster ME, Hobbs CA, Robbins JM, Collins RT, **Honein MA**. Factors associated with hospital utilization among patients aged 1-64 years with congenital heart defects, Arkansas 2006-2011. *Birth Defects Research Part A: Clinical and Molecular Teratology*, 2015;103(7):589-96.
93. Reefhuis J, Devine O, Friedman J, Louik C, Colarusso T, **Honein MA**, and the National Birth Defects Prevention Study. Specific SSRI antidepressants and birth defects risk: interpreting new data in the context of previous reports. *British Medical Journal*, 2015;351:h3190.
94. Reefhuis J, Gilboa SM, Anderka M, Browne ML, Feldkamp ML, Hobbs CA, Jenkins MM, Langlois PH, Newsome KB, Olshan AF, Romitti PA, Shapira SK, Shaw GM, Tinker SC, **Honein MA**, and the National Birth Defects Prevention Study. The National Birth Defects Prevention Study: a review of the methods. *Birth Defects Research Part A: Clinical and Molecular Teratology*, 2015;103(8):656-69.
95. Simeone RM, Oster ME, Hobbs CA, Robbins JM, Collins RT, **Honein MA**. A population-based study of hospital costs for hospitalizations of infants, children, and adults with a congenital heart defect, Arkansas 2006-2011. *Birth Defects Research Part A: Clinical and Molecular Teratology*, 2015;103(9):814-20.
96. Petersen LR, Jamieson DJ, Powers AM, **Honein MA**. Zika Virus. *N Engl J Med*. 2016 Apr 21;374(16):1552-63.
97. Gurvitz M, Burns KM, Brindis R, Broberg CS, Daniels CJ, Fuller SM, **Honein MA**, Khairy P, Kuehl KS, Landzberg MJ, Mahle WT, Mann DL, Marelli A, Newburger JW, Pearson GD, Starling RC, Tringali GR, Valente AM, Wu JC, Califf RM. Emerging Research Directions in Adult Congenital Heart Disease: A Report from an NHLBI/ACHA Working Group. *J Am Coll Cardiol*. 2016 Apr 26;67(16):1956-64.

98. Rasmussen SA, Jamieson DJ, **Honein MA**, Petersen LR. Zika Virus and Birth Defects--Reviewing the Evidence for Causality. *N Engl J Med*. 2016 May 19;374(20):1981-7.
99. Karwowski MP, Nelson JM, Staples JE, Fischer M, Fleming-Dutra KE, Villanueva J, Powers AM, Mead P, **Honein MA**, Moore CA, Rasmussen SA. Zika Virus Disease: A CDC Update for Pediatric Health Care Providers. *Pediatrics*. 2016 May;137(5).
100. Reefhuis J, Gilboa SM, Johansson MA, Valencia D, Simeone RM, Hills SL, Polen K, Jamieson DJ, Petersen LR, **Honein MA**. Projecting Month of Birth for At-Risk Infants after Zika Virus Disease Outbreaks. *Emerg Infect Dis*. 2016 May;22(5):828-32.
101. Pacheco O, Beltrán M, Nelson CA, Valencia D, Tolosa N, Farr SL, Padilla AV, Tong VT, Cuevas EL, Espinosa-Bode A, Pardo L, Rico A, Reefhuis J, González M, Mercado M, Chaparro P, Martínez Duran M, Rao CY, Muñoz MM, Powers AM, Cuéllar C, Helfand R, Huggett C, Jamieson DJ, **Honein MA**, Ospina Martínez ML. Zika Virus Disease in Colombia - Preliminary Report. *N Engl J Med*. 2016 Jun 15.
102. Farr S, Simeone RM, Gilboa SM, Oster ME, **Honein MA**. Limitations, depressive symptoms and quality of life among a population-based sample of young adults with congenital heart defects. *Birth Defects Res A Clin Mol Teratol*. 2016 Jul;106(7):580-6.
103. Meaney-Delman D, Oduyebo T, Polen KN, White JL, Bingham AM, Slavinski SA, Heberlein-Larson L, St George K, Rakeman JL, Hills S, Olson CK, Adamski A, Culver Barlow L, Lee EH, Likos AM, Muñoz JL, Petersen EE, Dufort EM, Dean AB, Cortese MM, Santiago GA, Bhatnagar J, Powers AM, Zaki S, Petersen LR, Jamieson DJ, **Honein MA**; U.S. Zika Pregnancy Registry Prolonged Viremia Working Group. Prolonged Detection of Zika Virus RNA in Pregnant Women. *Obstet Gynecol*. 2016 Oct;128(4):724-30.
104. Ellington SR, Devine O, Bertolli J, Martinez Quiñones A, Shapiro-Mendoza CK, Perez-Padilla J, Rivera-Garcia B, Simeone RM, Jamieson DJ, Valencia-Prado M, Gilboa SM, **Honein MA**, Johansson MA. Estimating the number of pregnant women infected with Zika virus and expected infants with microcephaly following the Zika outbreak in Puerto Rico, 2016. *JAMA Pediatr*. 2016 Oct 1;170(10):940-945.
105. Simeone RM, Tinker SC, Gilboa SM, Agopian AJ, Oster ME, Devine OJ, **Honein MA**. Proportion of selected congenital heart defects attributable to known or suspected risk factors. *Annals of Epidemiology*, 2016 Dec;26(12):838-845.
106. **Honein MA**, Dawson A, Petersen E, Jones AM, Lee EH, Yazdy MM, Ahmad N, MacDonald J, Evert N, Bingham A, Ellington SE, Shapiro-Mendoza CK, Oduyebo T, Fine AD, Brown CM, Sommer JN, Gupta J, Cavicchia P, Slavinski S, White JL, Owen SM, Petersen LR, Boyle C, Meaney-Delman D, Jamieson DJ, for the US Zika Pregnancy Registry Collaboration. Birth defects among fetuses and infants of US

women with laboratory evidence of possible maternal Zika virus infection during pregnancy. *JAMA*. 2017 Jan 3;317(1):59-68. doi: 10.1001/jama.2016.19006.

107. Gilboa SM, Mai CT, Shapiro-Mendoza CK, Cragan JD, Moore CA, Meaney-Delman DM, Jamieson DJ, **Honein MA**, Boyle CA. Population-based pregnancy and birth defects surveillance in the era of Zika virus. *Birth Defects Research*, 2017;109:372-378.

108. Lind JL, Interrante JD, Ailes EC, Gilboa SM, Khan S, Frey MT, Dawson AL, **Honein MA**, Dowling NF, Razzaghi H, Creanga AA, Broussard CS. Maternal Use of Opioids during Pregnancy and Congenital Malformations: A Systematic Review. *Pediatrics*. 2017 Jun;139(6).

109. Parra-Saavedra M, Reefhuis J, Piraquive JP, Gilboa SM, Badell ML, Moore CA, Mercado M, Valencia D, Jamieson DJ, Beltran M, Sanz-Cortes M, Rivera-Casas AM, Yopez M, Parra G, Ospina Martinez M, **Honein MA**. Serial Head and Brain Imaging of 17 Fetuses With Confirmed Zika Virus Infection in Colombia, South America. *Obstet Gynecol*. 2017 Jul;130(1):207-212.

110. Tolosa N, Tinker SC, Pacheco O, Valencia D, Botero DS, Tong VT, Mercado M, Gilboa SM, Gonzalez M, Nelson CA, Pardo L, Rao CY, Rico A, Moore M, Parra E, **Honein MA**, Opsina Martinez ML. Zika virus disease in children in Colombia, August 2015 – May 2016. *Paediatric and Perinatal Epidemiology*, 2017 Nov;31(6):537-545.

111. Jenkins MM, Reefhuis J, Herring AH, **Honein MA**. Impact of sample collection participation on the validity of estimated measures of association in the National Birth Defects Prevention Study when assessing gene-environment interactions. *Genetic Epidemiology* 2017 Dec;41(8):834-843.

112. Lathrop E, Romero L, Hurst S, Braceo N, Zapata L, Frey MT, Rivera MI, Berry-Bibee EN, **Honein MA**, Monroe J, Jamieson DJ. The Zika Contraception Access Network: Access to contraception in Puerto Rico during the Zika Virus Outbreak. *Lancet Public Health*. 2018 Feb;3(2):e91-e99.

113. Adamski A, Bertolli J, Castañeda-Orjuela C, Devine OJ, Johansson MA, Gonzalez Duarte MA, Tinker SC, Farr SL, Mercado Reyes MM, Tong VT, Pacheco Garcia OE, Valencia D, Cuellar Ortiz DA, **Honein MA**, Jamieson DJ, Ospina Martínez ML, Gilboa SM. Estimating the numbers of pregnant women infected with Zika virus and infants with congenital microcephaly in Colombia, 2015-2017. *Journal of Infection*, 2018 Jun;76(6):529-535.

114. Mann TZ, Haddad LB, Williams TR, Hills SL, Read JS, Dee DL, Dziuban EJ, Perez-Padilla J, Jamieson DJ, Honein MA, Shapiro-Mendoza CK. Breast Milk Transmission of Flaviviruses in the Context of Zika Virus: A Systematic Review. *Paediatric and Perinatal Epidemiology*, 2018 Jun 8. doi: 10.1111/ppe.12478.

115. Brittain AW, August EM, Romero L, Sheahan M, Krashing J, Ntansah C, Honein MA, Jamieson DJ, Ellis EM, Davies MS, Lathrop E. Community Perspectives on Contraception in the Context of the Zika Virus in the US Virgin Islands: Implications for Communication and Messaging. *Women's Health Issues, 2019 (epublished 13 March 2019)*.
116. Jenkins KJ, Botto LD, Correa A, Foster E, Kupiec JK, Marino BS, Oster ME, Stout KK, **Honein MA**. Public Health Approach to Improve Outcomes for Congenital Heart Disease Across the Life Span. *J Am Heart Assoc.* 2019 Apr 16;8(8):e009450.
117. Frey MT, Meaney-Delman D, Bowen V, Yazdy MM, Watkins SM, Thorpe PG, **Honein MA**. Surveillance for Emerging Threats to Pregnant Women and Infants. *Journal of Womens Health* 2019; 28(8):1031-1036.
118. Loudin S, Haas J, Payne M, Linz MF, Meaney-Delman D, **Honein MA**, Saunders A. Identifying Co-exposure to Opiates and Gabapentin During Pregnancy. *J Pediatr.* 2019 Oct 23. pii: S0022-3476(19)31191-6.
119. Mercado Reyes M, Ailes EC, Daza M, Tong VT, Osorio J, Valencia D, Rico Turca A, Galang RR, Gonzalez Duarte M, Ricaldi JN, Anderson KN, Kamal N, Thomas JD, Villanueva J, Burkel VK, Meaney-Delman D, Gilboa SM, **Honein MA**, Jamieson DJ, Ospina Martinez M. Zika virus testing of amniotic fluid in Colombia. 2020, *In press*, American Journal of Obstetrics and Gynecology.
120. Galang R, Avila Mellizo GA, Valencia D, Daza Calero M, Tong VT, Bermudez AJ, Gilboa S, Rico Turca A, Cates J, Pacheco Garcia O, Winfield CM, Prieto Alvarado F, **Honein MA**, Cortés LJ, Moore CA, Ospina Martínez ML. Etiologic classification of microcephaly and birth defects of the central nervous system during the Zika virus epidemic – Colombia, September 2015–April 2017. Under review.
121. Ailes EC, Zimmerman J, Lind JN, Fan F, Shi K, Reefhuis J, Broussard CS, Frey MT, Cragan JD, Petersen EE, Polen KD, **Honein MA**, Gilboa SM. Using supervised learning methods to develop a list of prescription medications of greatest concern during pregnancy. Under review.
122. Downing K, Tepper NK, Simeone RM, Ailes EC, Gurvitz M, Boulet SL, **Honein MA**, Howards PP, Valente AM, Farr SL. Adverse outcomes and conditions of pregnancy among privately-insured women with and without congenital heart defects, 2007-2014. Under review.
123. Ospina Martínez ML, Tong VT, Gonzalez M, Valencia D, Mercado M, Gilboa SM, Rodriguez AY, Tinker SC, Rico A, Winfield CM, Pardo L, Thomas JD, Avila G, Villanueva JM, Gomez S, Jamieson DJ, Frieto F, Meaney-Delman D, Pacheco O, **Honein MA**. Zika Virus Disease in Colombia – Final Report. Under review.

OTHER PUBLICATIONS (Editorials, MMWRs, Other)

1. CDC. Trends in infant mortality attributable to birth defects – United States, 1980 - 1995. *MMWR Morbid Mortal Wkly Rep*, 1998; 47(37):773-778.
2. CDC. Infantile hypertrophic pyloric stenosis following pertussis prophylaxis with erythromycin, Knoxville, TN, 1999. *MMWR Morbid Mortal Wkly Rep R*, 1999; 48(49):1117-1120.
3. **Honein MA**, Paulozzi LJ. RE: Cost -effectiveness of isotretinoin. [letter to the editor] *Dermatology*, 1999; 198:404-406.
4. CDC. Accutane®-exposed pregnancies – California, 1999. *MMWR Morbid Mortal Wkly Rep*, 2000; 49(2):28-31.
5. **Honein MA**, Rasmussen SA. Further evidence for an association between maternal smoking and craniosynostosis [research letter]. *Teratology*, 2000; 62:145-146.
6. CDC. Barriers to Dietary Control Among Pregnant Women with Phenylketonuria --- United States, 1998—2000. *MMWR Morbid Mortal Wkly Rep*, 2002; 51:117-120.
7. **Honein MA**, Moore CA, Lyon Daniel K, Erickson JD. Problems with informing women adequately about teratogen risk: some barriers to preventing exposures to known teratogens. *Teratology*, 2002; 65:202-204.
8. CDC. Spina bifida and anencephaly prevalence--United States, 1991-2001. *MMWR Recomm Rep* 2002 Sep 13;51(RR-13):9-11.
9. CDC. Loratadine (Claritin®) and hypospadias, data from the National Birth Defects Prevention Study, U.S.A. 1997-2000. *MMWR Morbid Mortal Wkly Rep*, 2004;53(10):219-221.
10. CDC. Improved national prevalence estimates for 18 selected major birth defects-- United States, 1999-2001. *MMWR Morb Mortal Wkly Rep*. 2006 Jan 6;54(51):1301-5.
11. CDC. Racial/ethnic differences in the birth prevalence of spina bifida - United States, 1995-2005. *MMWR Morb Mortal Wkly Rep*. 2009 Jan 9;57(53):1409-13.
12. Reefhuis J, **Honein MA**, Schieve LA, Correa A, Hobbs CA, Rasmussen SA. Reply: ART and major structural birth defects in the USA [letter]. *Human Reproduction*, 2009; 24:1766.
13. CDC. Novel Influenza A (H1N1) Virus Infections in Three Pregnant Women --- United States, April--May 2009. *MMWR Morb Mortal Wkly Rep*. 2009 May 15;58(18):497-500.

14. CDC. Surveillance for Pediatric Deaths Associated with 2009 Pandemic Influenza A (H1N1) Virus Infection — United States, April–August 2009. *MMWR Morb Mortal Wkly Rep.* 2009 Sep 4;58(34):941-947.
15. CDC. Severe 2009 H1N1 influenza virus infection in pregnant women in New York City, 2009. *MMWR Morb Mortal Wkly Rep.* 2010 Mar 26;59(11):321-326.
16. CDC. Racial differences by gestational age in neonatal deaths attributable to congenital heart defects --- United States, 2003-2006. *MMWR Morb Mortal Wkly Rep.* 2010 Sep 24;59(37):1208-11.
17. Rasmussen SA, Riehle-Colarusso T, Shapira SK, **Honein MA**, Reefhuis J; National Birth Defects Prevention Study. Letter to the editor: Ventricular septal defects and the National Birth Defects Prevention Study. *Birth Defects Res A Clin Mol Teratol.* 2011;91(1):66.
18. Reefhuis J, Rasmussen SA, **Honein MA**. Letter to the editor: A randomized trial of prenatal versus postnatal repair of myelomeningocele. *New England Journal of Medicine* 2011;364(26):2555; author reply 2556.
19. CDC. Maternal and infant outcomes among severely ill pregnant and postpartum women with 2009 pandemic influenza A (H1N1) --- United States, April 2009--August 2010. *MMWR Morb Mortal Wkly Rep.* 2011 Sep 9; 60(35);1193-1196.
20. CDC. Severe influenza among children and young adults with neurologic and neurodevelopmental conditions – Ohio, 2011. *MMWR Morb Mortal Wkly Rep.* 2012 Jan 6; 60(51 & 52);1729-1733.
21. CDC. Assessment of Current Practices and Feasibility of Universal Screening for Critical Congenital Heart Defects in Georgia, 2012. *MMWR Morb Mortal Wkly Rep.* 2013 April 19; 62(15);288-291.
22. **Honein MA**, Gilboa SM, Broussard CS. The need for safer medication use in pregnancy (editorial). *Expert Review of Clinical Pharmacology*, 2013;6(5):453-5.
23. **Honein, MA**, Moore CA. The safety or risk of antihistamine use in pregnancy: reassuring data are helpful but not sufficient (editorial). *Journal of Allergy and Clinical Immunology: In Practice*, 2013;1:675-6.
24. **Honein MA**, Cragan JD. Balancing competing risks: perinatal exposure to macrolides increases the risk of infantile hypertrophic pyloric stenosis. Invited commentary for: *Evidence-Based Medicine*, 2014;19(6):239.
25. McCarty CL, Basler C, Karwowski M, Erme M, Nixon G, Kippes C, Allan T, Parrilla T, DiOrio M, Fijter Sd, Stone ND, Yost DA, Lippold SA, Regan JJ, **Honein MA**, Knust B,

Braden C. Response to importation of a case of Ebola Virus Disease - Ohio, October 2014. *MMWR Morb Mortal Wkly Rep.* 2014;63(46):1089-91.

26. Ailes EC, Dawson AL, Lind JN, Gilboa SM, Frey MT, Broussard CS, **Honein MA**. Opioid prescription claims among women of reproductive age - United States, 2008-2012. *MMWR Morb Mortal Wkly Rep.* 2015 Jan 23;64(2):37-41.

27. Simeone RM, Feldkamp ML, Reefhuis J, Mitchell AA, Gilboa SM, **Honein MA**, Iskander J. Grand Rounds: Understanding the causes of major birth defects — steps to prevention. *MMWR Morb Mortal Wkly Rep.* 2015; 64(39):1104-1107.

28. Jones AM, Isenburg J, Salemi JL, Arnold KE, Mai CT, Aggarwal D, Arias W, Carrino GE, Ferrell E, Folorunso O, Ibe B, Kirby RS, Krapfl HR, Marengo LK, Mosley BS, Nance AE, Romitti PA, Spadafino J, Stock J, **Honein MA**. Increasing prevalence of gastroschisis – 14 states, 1995—2012. *MMWR Morb Mortal Wkly Rep.* 2016; 65(2):23-6.

29. Staples JE, Dziuban EJ, Fischer M, Cragan JD, Rasmussen SA, Cannon MJ, Frey MT, Renquist CM, Lanciotti RS, Muñoz JL, Powers AM, **Honein MA**, Moore CA. Interim guidelines for the evaluation and testing of infants with possible congenital zika virus infection - United States, 2016. *MMWR Morb Mortal Wkly Rep.* 2016; 65(3):63-7.

30. Dawson AL, Ailes EC, Gilboa SM, Simeone RM, Lind JN, Farr SL, Broussard CS, Reefhuis J, Carrino G, Biermann J, **Honein MA**. Antidepressant prescription claims among reproductive-aged women with private employer-sponsored insurance - United States 2008-2013. *MMWR Morb Mortal Wkly Rep.* 2016; 65(3):41-6.

31. Oduyebo T, Petersen EE, Rasmussen SA, Mead PS, Meaney-Delman D, Renquist CM, Ellington SR, Fischer M, Staples JE, Powers AM, Villanueva J, Galang RR, Dieke A, Muñoz JL, **Honein MA**, Jamieson DJ. Update: Interim guidelines for health care providers caring for pregnant women and women of reproductive age with possible zika virus exposure - United States, 2016. *MMWR Morb Mortal Wkly Rep.* 2016; 65(5):122-7.

32. Fleming-Dutra KE, Nelson JM, Fischer M, Staples JE, Karwowski MP, Mead P, Villanueva J, Renquist CM, Minta AA, Jamieson DJ, **Honein MA**, Moore CA, Rasmussen SA. Update: Interim guidelines for health care providers caring for infants and children with possible zika virus infection - United States, February 2016. *MMWR Morb Mortal Wkly Rep.* 2016; 65(7):182-7.

33. Meaney-Delman D, Hills SL, Williams C, Galang RR, Iyengar P, Hennenfent AK, Rabe IB, Panella A, Oduyebo T, **Honein MA**, Zaki S, Lindsey N, Lehman JA, Kwit N, Bertolli J, Ellington S, Igbinsosa I, Minta AA, Petersen EE, Mead P, Rasmussen SA, Jamieson DJ. Zika virus infection among U.S. pregnant travelers - August 2015-February 2016. *MMWR Morb Mortal Wkly Rep.* 2016; 65(8):211-4.

34. Olson CK, Iwamoto M, Perkins KM, Polen KN, Hageman J, Meaney-Delman D, Igbinosa II, Khan S, **Honein MA**, Bell M, Rasmussen SA, Jamieson DJ. Preventing transmission of zika virus in labor and delivery settings through implementation of standard precautions - United States, 2016. *MMWR Morb Mortal Wkly Rep.* 2016; 65(11):290-2.
35. Petersen EE, Polen KN, Meaney-Delman D, Ellington SR, Oduyebo T, Cohn A, Oster AM, Russell K, Kawwass JF, Karwowski MP, Powers AM, Bertolli J, Brooks JT, Kissin D, Villanueva J, Muñoz-Jordan J, Kuehnert M, Olson CK, **Honein MA**, Rivera M, Jamieson DJ, Rasmussen SA. Update: Interim Guidance for Health Care Providers Caring for Women of Reproductive Age with Possible Zika Virus Exposure — United States, 2016. *MMWR Morb Mortal Wkly Rep.* ePub: 25 March 2016.
36. Tepper NK, Goldberg HI, Bernal MI, Rivera B, Frey MT, Malave C, Renquist CM, Bracero NJ, Dominguez KL, Sanchez RE, Shapiro-Mendoza CK, Cuevas Rodriguez BR, Simeone RM, Pesik NT, Barfield WD, Ko JY, Galang RR, Perez-Padilla J, Polen KND, **Honein MA**, Rasmussen SA, Jamieson DJ. Estimating Contraceptive Needs and Increasing Access to Contraception in Response to the Zika Virus Disease Outbreak — Puerto Rico, 2016. *MMWR Morb Mortal Wkly Rep.* ePub: 25 March 2016.
37. Simeone RM, Shapiro-Mendoza CK, Meaney-Delman D, Petersen EE, Galang RR, Oduyebo T, Rivera-Garcia B, Valencia-Prado M, Newsome KB, Pérez-Padilla J, Williams TR, Biggerstaff M, Jamieson DJ, **Honein MA**; Zika and Pregnancy Working Group. Possible Zika Virus Infection Among Pregnant Women - United States and Territories, May 2016. *MMWR Morb Mortal Wkly Rep.* 2016 May 27;65(20):514-9.
38. Oduyebo T, Igbinosa I, Petersen EE, Polen KN, Pillai SK, Ailes EC, Villanueva JM, Newsome K, Fischer M, Gupta PM, Powers AM, Lampe M, Hills S, Arnold KE, Rose LE, Shapiro-Mendoza CK, Beard CB, Muñoz JL, Rao CY, Meaney-Delman D, Jamieson DJ, **Honein MA**. Update: Interim Guidance for Health Care Providers Caring for Pregnant Women with Possible Zika Virus Exposure - United States, July 2016. *MMWR Morb Mortal Wkly Rep.* 2016 Jul 25;65(29):739-44.
39. Boulet SL, D'Angelo DV, Morrow B, Zapata L, Berry-Bibee E, Rivera M, Ellington S, Romero L, Lathrop E, Frey M, Williams T, Goldberg H, Warner L, Harrison L, Cox S, Pazol K, Barfield W, Jamieson DJ, **Honein MA**, Kroelinger CD. Contraceptive Use Among Nonpregnant and Postpartum Women at Risk for Unintended Pregnancy, and Female High School Students, in the Context of Zika Preparedness - United States, 2011-2013 and 2015. *MMWR Morb Mortal Wkly Rep.* 2016 Aug 5;65(30):780-7.
40. Petersen LR, Jamieson DJ, **Honein MA**. Zika Virus [letter]. *N Engl J Med.* 2016 Jul 21;375(3):294-5. doi: 10.1056/NEJMc1606769. Epub 2016 Jun 29.
41. Petersen EE, Meaney-Delman D, Neblett-Fanfair R, Havers F, Oduyebo T, Hills SL, Rabe IB, Lambert A, Abercrombie J, Martin SW, Gould CV, Oussayef N, Polen KN, Kuehnert MJ, Pillai SK, Petersen LR, **Honein MA**, Jamieson DJ, Brooks JT. Update:

Interim Guidance for Preconception Counseling and Prevention of Sexual Transmission of Zika Virus for Persons with Possible Zika Virus Exposure - United States, September 2016. *MMWR Morb Mortal Wkly Rep.* 2016 Oct 7;65(39):1077-1081.

42. Cuevas EL, Tong VT, Rozo N, Valencia D, Pacheco O, Gilboa SM, Mercado M, Renquist CM, Gonzalez M, Ailes EC, Duarte C, Godoshian V, Sancken C, Turca AMR, Calles DL, Ayala M, Morgan P, Perez ENT, Bonilla HQ, Gomez RC, Estupinan AC, Gunturiz ML, Meaney-Delman D, Jamieson DJ, **Honein MA**, Ospina Martinez ML. Preliminary report of microcephaly potentially associated with Zika virus infection during pregnancy — Colombia, February through November 2016. *MMWR Morb Mortal Wkly Rep.* 2016 Dec 16;65(49):1409-1413.

43. **Honein MA**, Jamieson DJ. Monitoring and Preventing Congenital Zika Syndrome [editorial]. *N Engl J Med.* 2016 Dec 15;375(24):2393-2394.

44. Oussayef NL, Pillai SK, **Honein MA**, Ben Beard C, Bell B, Boyle CA, Eisen LM, Kohl K, Kuehnert MJ, Lathrop E, Martin SW, Martin R, McAllister JC, McClune EP, Mead P, Meaney-Delman D, Petersen B, Petersen LR, Polen KN, Powers AM, Redd SC, Sejvar JJ, Sharp T, Villanueva J, Jamieson DJ. Zika Virus -10 Public Health Achievements in 2016 and Future Priorities. *MMWR Morb Mortal Wkly Rep.* 2017 Jan 6;65(52):1482-1488.

45. Cragan JD, Mai CT, Petersen EE, Liberman RF, Forestieri NE, Stevens AC, Delaney A, Dawson AL, Ellington SR, Shapiro-Mendoza CK, Dunn JE, Higgins CA, Meyer RE, Williams T, Polen KN, Newsome K, Reynolds M, Isenburg J, Gilboa SM, Meaney-Delman DM, Moore CA, Boyle CA, **Honein MA**. Baseline Prevalence of Birth Defects Associated with Congenital Zika Virus Infection - Massachusetts, North Carolina, and Atlanta, Georgia, 2013-2014. *MMWR Morb Mortal Wkly Rep.* 2017 Mar 3;66(8):219-222.

46. D'Angelo DV, Salvesen von Essen B, Lamias MJ, Shulman H, Hernandez-Virella WI, Taraporewalla AJ, Vargas MI, Harrison L, Ellington SR, Soto L, Williams T, Rodriguez A, Shapiro-Mendoza CK, Rivera B, Cox S, Pazol K, Rice ME, Dee DL, Romero L, Lathrop E, Barfield W, Smith RA, Jamieson DJ, **Honein MA**, Deseda C, Warner L. Measures Taken to Prevent Zika Virus Infection During Pregnancy - Puerto Rico, 2016. *MMWR Morb Mortal Wkly Rep.* 2017 Jun 9;66(22):574-578.

47. Shapiro-Mendoza CK, Rice ME, Galang RR, Fulton AC, VanMaldeghem K, Prado MV, Ellis E, Anesi MS, Simeone RM, Petersen EE, Ellington SR, Jones AM, Williams T, Reagan-Steiner S, Perez-Padilla J, Deseda CC, Beron A, Tufa AJ, Rosinger A, Roth NM, Green C, Martin S, Lopez CD, deWilde L, Goodwin M, Pagano HP, Mai CT, Gould C, Zaki S, Ferrer LN, Davis MS, Lathrop E, Polen K, Cragan JD, Reynolds M, Newsome KB, Huertas MM, Bhatangar J, Quiñones AM, Nahabedian JF, Adams L, Sharp TM, Hancock WT, Rasmussen SA, Moore CA, Jamieson DJ, Munoz-Jordan JL, Garstang H, Kambui A, Masao C, **Honein MA**, Meaney-Delman D; Zika Pregnancy and Infant Registries Working Group. Pregnancy Outcomes After Maternal Zika Virus Infection

During Pregnancy - U.S. Territories, January 1, 2016-April 25, 2017. *MMWR Morb Mortal Wkly Rep.* 2017 Jun 16;66(23):615-621.

48. Reagan-Steiner S, Simeone R, Simon E, Bhatnagar J, Oduyebo T, Free R, Denison AM, Rabeneck DB, Ellington S, Petersen E, Gary J, Hale G, Keating MK, Martines RB, Muehlenbachs A, Ritter J, Lee E, Davidson A, Connors E, Scotland S, Sandhu K, Bingham A, Kassens E, Smith L, St George K, Ahmad N, Tanner M, Beavers S, Miers B, VanMaldeghem K, Khan S, Rabe I, Gould C, Meaney-Delman D, **Honein MA**, Shieh WJ, Jamieson DJ, Fischer M, Zaki SR; U.S. Zika Pregnancy Registry Collaboration; Zika Virus Response Epidemiology and Surveillance Task Force Pathology Team. Evaluation of Placental and Fetal Tissue Specimens for Zika Virus Infection - 50 States and District of Columbia, January-December, 2016. *MMWR Morb Mortal Wkly Rep.* 2017 Jun 23;66(24):636-643.

49. Oduyebo T, Polen KD, Walke HT, Reagan-Steiner S, Lathrop E, Rabe IB, Kuhnert-Tallman WL, Martin SW, Walker AT, Gregory CJ, Ades EW, Carroll DS, Rivera M, Perez-Padilla J, Gould C, Nemhauser JB, Ben Beard C, Harcourt JL, Viens L, Johansson M, Ellington SR, Petersen E, Smith LA, Reichard J, Munoz-Jordan J, Beach MJ, Rose DA, Barzilay E, Noonan-Smith M, Jamieson DJ, Zaki SR, Petersen LR, **Honein MA**, Meaney-Delman D. Update: Interim Guidance for Health Care Providers Caring for Pregnant Women with Possible Zika Virus Exposure - United States (Including U.S. Territories), July 2017. *MMWR Morb Mortal Wkly Rep.* 2017 Jul 28;66(29):781-793.

50. Prakalapakorn SG, Meaney-Delman D, **Honein MA**, Rasmussen SA. The eyes as a window to improved understanding of the prenatal effects of Zika virus infection. *Journal of American Association for Pediatric Ophthalmology and Strabismus.* 2017 Aug;21(4):259-261.

51. Adebajo T, Godfred-Cato S, Fischer M, Staples E, Viens L, Kuhnert-Tallmann W, Walke H, Oduyebo T, Polen K, Peacock G, Meaney-Delman D, **Honein MA**, Rasmussen SA, Moore CA. Update: Interim Guidance for the Diagnosis, Evaluation, and Management of Infants with Possible Congenital Zika Virus Infection – United States, October 2017. *MMWR Morb Mortal Wkly Rep.* 2017 Oct 20;66(41):1089-1099.

52. Delaney A, Mai C, Smoots A, Cragan J, Ellington S, Langlois P, Breidenbach R, Fornoff J, Dunn J, Yazdy M, Scotto-Rosato N, Sweatlock J, Fox D, Palacios J, Forestieri N, Leedom V, Smiley M, Nance A, Lake-Burger H, Romitti P, Fall C, Valencia Prado M, Barton J, Bryan JM, Arias W, Viner Brown S, Kimura J, Mann S, Martin B, Orantes L, Taylor A, Nahabedian J, Akosa A, Song Z, Martin S, Ramlal R, Shapiro-Mendoza C, Isenburg J, Moore CA, Gilboa S, **Honein MA**. Population-based surveillance of birth defects potentially related to Zika virus infection — 15 U.S. States and Territories, 2016. *MMWR Morb Mortal Wkly Rep.* 2018 Jan 26;67(3):91-96.

53. Fitzgerald B, Boyle C, **Honein MA**. Birth Defects Potentially Related to Zika Virus Infection During Pregnancy in the United States. *JAMA*. 2018 Jan 25. doi: 10.1001/jama.2018.0126.
54. **Honein MA**. Recognizing the Global Impact of Zika Virus Infection during Pregnancy. *N Engl J Med*. 2018 Mar 15;378(11):1055-1056. doi: 10.1056/NEJMe1801398.
55. Jenkins KJ, **Honein MA**. Public Health Approach to Decrease Mortality for Congenital Heart Defects: Dying Too Soon. *J Am Coll Cardiol*. 2018 May 29;71(21):2447-2449.
56. Rasmussen SA, Barfield W, **Honein MA**. Protecting Mothers and Babies: A Delicate Balancing Act. *N Engl J Med*. 2018 Sep 6;379(10):907-909.
57. Rice ME, Galang RR, Roth NM, Ellington SR, Moore CA, Valencia Prado M, Ellis EM, John Tufa A, Taulung LA, Alfred JA, Perez-Padilla J, Delgado-López CA, Zaki SR, Reagan-Steiner S, Bhatnagar J, Nahabedian JF, Reynolds MR, Yeargin-Allsopp M, Viens L, Olson SM, Jones AM, Baez-Santiago MA, Oppong-Twene P, VanMaldeghem K, Simon EL, Moore JT, Polen KD, Hillman B, Ropeti R, Nieves-Ferrer L, Marcano-Huertas M, Masao CA, Anzures EJ, Hansen RL, Pérez-Gonzalez S, Espinet-Crespo C, Luciano-Roman, Shapiro-Mendoza CK, Gilboa SM, **Honein MA**. Vital Signs: Zika-Associated Birth Defects and Neurodevelopmental Abnormalities Possibly Associated with Congenital Zika Virus Infection - U.S. Territories and Freely Associated States, 2018. *MMWR Morb Mortal Wkly Rep*. 2018 Aug 10;67(31):858-867.
58. Polen KD, Gilboa SM, Hills S, Oduyebo T, Kohl KS, Brooks JT, Adamski A, Simeone RM, Walker AT, Kissin DM, Petersen LR, **Honein MA**, Meaney-Delman D. Update: Interim Guidance for Preconception Counseling and Prevention of Sexual Transmission of Zika Virus for Men with Possible Zika Virus Exposure - United States, August 2018. *MMWR Morb Mortal Wkly Rep*. 2018 Aug 10;67(31):868-871.
59. **Honein MA**, Jamieson DJ. Revealing the Effects of Zika—Detection of Brain Abnormalities and Other Disabilities Associated With Congenital Infection. *JAMA Pediatrics*, *JAMA Pediatr*. 2019 Jan 1;173(1):16-18.
60. **Honein MA**, Boyle C, Redfield RR. Public Health Surveillance of Prenatal Opioid Exposure in Mothers and Infants. *Pediatrics*. 2019 Mar;143(3).
61. **Honein MA**, Cetron MS, Meaney-Delman D. Endemic Zika virus transmission: implications for travellers. *Lancet Infect Dis*. 2019 Apr;19(4):349-351.
62. Olson SM, Delaney A, Jones AM, Carr CP, Liberman RF, Forestieri NE, Tong VT, Gilboa SM, **Honein MA**, Moore CA, Cragan JD. Updated baseline prevalence of birth defects potentially related to Zika virus infection [research letter]. *Birth Defects Research*, 2019 Aug 1;111(13):938-940.

63. Redfield RR, Modi S, Moore C, Delaney A, **Honein MA**, Tomlinson HL. Healthcare Autonomy of Women Living with HIV. *New England Journal of Medicine*, 2019 Aug 29;381(9):798-800.
64. Kroelinger CD, Rice ME, Cox S, Hickner HR, Weber MK, Romero L, Ko JY, Addison D, Mueller T, Shapiro-Mendoza C, Fehrenbach SN, **Honein MA**, Barfield WD. State Strategies to Address Opioid Use Disorder Among Pregnant and Postpartum Women and Infants Prenatally Exposed to Substances, Including Infants with Neonatal Abstinence Syndrome. *MMWR Morb Mortal Wkly Rep*. 2019 Sep 13;68(36):777-783.
65. Gilboa SM, Gregory CJ, **Honein MA**. Better Surveillance Needed to Protect Mothers and Infants from Zika. *Lancet Infect Dis*. 2019 Oct;19(10):1047-1048.
66. **Honein MA**, Woodworth KR, Gregory CJ. Neurodevelopmental Abnormalities Associated With In Utero Zika Virus Infection in Infants and Children-The Unfolding Story. *JAMA Pediatr*. 2020 Jan 6.
67. Smoots AN, Olson SM, Cragan J, Delaney A, Roth NM, Godfred-Cato S, Jones AM, Nahabedian J, Fornoff J, Sandidge T, Yazdy M, Higgins C, Olney RS, Eckert V, Forkner A, Fox DJ, Stolz A, Crawford K, Cho SJ, Knapp M, Ahmed MF, Lake-Burger H, Elmore A, Langlois P, Breidenbach R, Nance A, Denson L, Caton L, Forestieri N, Bergman K, Humphries BK, Leedom VO, Tran T, Johnson J, Valencia-Prado M, Pérez-González S, Romitti P, Fall C, Bryan JM, Barton J, Arias W, St. John K, Mann S, Kimura J, Orantes L, Martin B, de Wilde L, Ellis EM, Song Z, Akosa A, Goodroe C, Ellington SR, Tong VT, Gilboa SM, Moore CA, **Honein MA**. Population-Based Surveillance for Birth Defects Potentially Related to Zika Virus Infection — 22 States and Territories, January 2016–June 2017. 2020, *In press MMWR Morb Mortal Wkly Rep*.
68. Meaney-Delman D, Oussayef NL, **Honein M**, Nelson CA. Plague and Pregnancy: Why Special Considerations are Needed. 2020, *In press, Clinical Infectious Diseases*.

BOOK CHAPTERS/DISSERTATION

Honein MA. A case-control study of risk factors for HIV serostatus among treated tuberculosis patients in the Republic of Djibouti. Los Angeles: University of California at Los Angeles (UCLA), 1995.

Honein MA, Rasmussen SA. Promises and Perils of Large Epidemiological Studies of Congenital Heart Defects (book chapter). *Congenital Heart Defects: From Origin to Treatment*. Edited by Wyszynski DF, Correa-Villasenor A, Graham TP, Oxford University Press, New York. Published December 2009.

Honein MA, Reefhuis J. Tobacco exposure and congenital defects (section). *Surgeon General's Report on Smoking, 2014*. Atlanta, GA: U.S. Department of Health and

Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health.

SELECTED PRESENTATIONS AT NATIONAL SCIENTIFIC MEETINGS

1. Detecting Prescribed Teratogens. Proceedings of the 47th Annual Epidemic Intelligence Service (EIS) Conference, p. 60. April 1998, CDC. Atlanta, GA.
2. Assessing the sensitivity of the 'Gold Standard' in Birth Defects Surveillance. Proceedings of the 47th Annual Epidemic Intelligence Service (EIS) Conference, p.20. April 1998, CDC. Atlanta, GA.
3. Pregnancy drug registries and their role in monitoring fetal exposures. [presented at the Teratology Society Meetings, June 1998]. *Teratology*, 1998; 57:220.
4. Surveillance of neural tube defects. Preventing neural tube defects with folic acid Conference, National Birth Defects Prevention Network, January 1999, Arlington, VA.
5. Family history, maternal smoking, and clubfoot: a possible gene-environment interaction. Proceedings of the 48th Annual Epidemic Intelligence Service (EIS) Conference, p.13. April 1999, CDC. Atlanta, GA.
6. The impact of folic acid fortification on the birth prevalence of neural tube defects in the United States. [*poster presentation and oral symposium*] *Proceedings of the Society for Pediatric and Perinatal Epidemiology, June 13-14, 2000; Abstract A14*. Seattle, WA.
7. Accutane[®]-exposed pregnancies. [abstract presented at the 2000 Teratology Society Meetings) *Teratology*, 2000;61:Abstract19, page 442.
8. Maternal subfertility and congenital renal anomalies. Oral Presentation at the Teratology Society Meeting, Montreal, Quebec, Canada. June 2001.
9. Maternal smoking, environmental tobacco smoke, and the risk of oral clefts. National Birth Defects Prevention Network Annual Meeting, Scottsdale, Arizona, January 2005.
10. Use of Non-prescription medications during pregnancy among control-mothers. National Birth Defects Prevention Network Annual Meeting, Scottsdale, Arizona, January 2005.
11. Findings and Future of the National Birth Defects Prevention Study. National Birth Defects Prevention Network Annual Meeting, Washington, D.C., January 2006.
12. Maternal smoking and major birth defects. National Birth Defects Prevention Network, Washington, D.C., February 2008.

13. Early-Pregnancy Opioid Analgesic Treatment and Risk for Congenital Heart Defects — United States, 1997–2004. Teratology Society Meeting, June 2009, Puerto Rico.
14. Pandemic Influenza A (H1N1) Virus Illness Among Pregnant Women in the United States, 2009. April, 19, 2010. National Immunization Conference, Atlanta, Georgia.
15. Understanding risk factors for orofacial clefts and craniosynostosis: The National Birth Defects Prevention Study. Keynote Address: American Cleft Palate-Craniofacial Association. April 6, 2011, Puerto Rico.
16. Use of special education services by children with orofacial clefts. American Cleft Palate-Craniofacial Association. April 6, 2011, Puerto Rico.
17. Public health impact of adult congenital heart disease. American Heart Association. November 18, 2013, Dallas, Texas.
18. Exploring the Link Between Zika Virus and Adverse Pregnancy and Birth Outcomes. Ninth Pan-American Congress of Neonatology, October, 14, 2016, Cartagena, Colombia.
18. Adverse pregnancy and infant outcomes associated with maternal Zika virus infection. American Society of Tropical Medicine and Hygiene. November 14, 2016, Atlanta, Georgia.
19. Birth Defects Linked to Congenital Zika Infection: Magnitude of the Risk, Zika Symposium. December 1, 2016. Bogota, Colombia.
20. Zika Virus Infection and Pregnancy. Epidemic Intelligence Service (EIS) Annual Conference, April 26, 2017, Atlanta, GA.
21. Zika Virus Infection: Maternal Child Health and Health Equity. Council of State and Territorial Epidemiologists (CSTE) Annual Meeting Workshop, June 4, 2017, Boise, Idaho.
22. The Zika Epidemic: An Update from the CDC. Teratology Society Annual Meeting, June 28, 2017, Denver, Colorado.
23. CDC's Zika Pregnancy and Infant Research and Surveillance. ID Week Annual Meeting, October 5, 2017, San Diego, California.
24. Protecting Mothers and Babies from Emerging and Known Health Threats: The Critical Role of Birth Defects Surveillance. National Birth Defects Prevention Network Meeting, March 12, 2018, Atlanta, Georgia.

25. Zika Virus: Evolution of Diagnostics and Neurodevelopmental Outcomes in Congenital Zika. ID Week, October 6, 2018, San Francisco, California.
26. Travel to a Zika Endemic Region – Should My Patient Worry? 16th Conference of the International Society of Travel Medicine, June 8, 2019, Washington, D.C.
27. Pregnancy & Birth Outcomes among Colombian Women with Zika Virus Disease in 3 Surveillance Sites: Proyecto Vigilancia de Embarazadas con Zika (VEZ). IDWeek, October 4, 2019, Washington, D.C.

SELECTED INVITED PRESENTATIONS AND LEADERSHIP ROLES

1. Invited presentation: “Collaboration in the National Birth Defects Prevention Study.” Research meeting of the Organization of Teratology Information Services, Houston, TX, January, 2001.
2. Invited presentation: “Problems with informing women adequately about teratogen risk: some barriers to preventing exposures to known teratogens.” Teratology Society Meeting, Quebec, Canada. June 2001.
3. Invited roundtable leader: The epidemiology of birth defects: lumping versus splitting in analysis. Society for Epidemiologic Research, Atlanta, June 2003.
4. Invited presentation: Methodology for ascertaining herbal use in various studies. Planning workshop for the National Children’s Study. Atlanta, December 2003.
5. Invited roundtable leader: Nonparticipation in the genetic component of epidemiologic studies. Society for Epidemiologic Research, Salt Lake City, June 2004.
6. Proposed and moderated symposium on “The future of folic acid - beyond a role in the prevention of NTDS.” Society for Epidemiologic Research, Salt Lake City, June 2004.
7. Invited presentation: “National Birth Defects Prevention Study: a model for interdisciplinary research on craniofacial anomalies.” World Health Organization (WHO) Meeting on International collaboration to reduce the health-care burden of craniofacial anomalies, Geneva, December 2004.
8. Invited presentation: “Ensuring the safe use of medications during pregnancy.” Seminar for faculty of the Mercer University Southern School of Pharmacy. Atlanta, GA. October 2005.
9. Invited presentation: “Unraveling clues to the causes of birth defects.” Congressional Briefing organized by the March of Dimes, Washington, D.C., January 31, 2006.

10. Invited presentation: "Update on CDC's public health research priorities for craniofacial malformations." National Foundation for Facial Reconstruction Executive Board Meeting, New York, NY, September 2006.
11. Invited presentation: "The birth defects program at the CDC and clubfoot." International Clubfoot Symposium. Iowa City, Iowa, Sept. 12, 2007.
12. Invited presentation: "An update on the National Birth Defects Prevention Study." NICHD Extramural Research Program, Baltimore, MD. May, 2008
13. Invited presentation: "Large multi-site epidemiologic studies of birth defects: challenges and opportunities", Teratology Society Meeting, Monterey, CA. July 1, 2008.
14. Epidemiological leadership on the CDC pandemic influenza response for pregnant women:
 - Update presented on Clinician Outreach and Communication Activity (COCA) call to alert health care providers and public health professionals about the needed surveillance of severe influenza in pregnant women. Aug. 5, 2009.
 - Update to CDC's Influenza leadership on a reporting line to capture severe influenza and deaths among pregnant women. Sept. 28, 2009.
 - CDC Pregnancy Flu Line: Accomplishments and Continuing Challenges. Presentation to Influenza Response Leadership. February 2, 2010.
15. Proposed and co-moderated symposium: "2009 pandemic influenza a (H1N1) virus infection: epidemiology and response." Society for Epidemiologic Research, Seattle, June 2010.
16. Invited roundtable leader: 2009 H1N1 Influenza: Epidemiology in an Emerging Pandemic. Society for Epidemiologic Research, Seattle, June 2010.
17. Invited presentation: Improving our understanding of the risk of medications during pregnancy: data from the National Birth Defects Prevention Study. Department of Epidemiology, Rollins School of Public Health, Emory University. Atlanta. November 2010.
18. Invited presentation: CDC's Public Health Research to Prevent Major Birth Defects. Seminar Series at University of Georgia, Athens, September 2011.
19. Invited presentation: Latest Information from Population Monitoring: Updates from the CDC National Center on Birth Defects and Developmental Disabilities. Workshop on: Environmental Influences on Neurodevelopment: Translating the Emerging Science into Public Health Policy. University of California, Los Angeles, January 2012.
20. Leadership for CDC's Meeting of Experts on Congenital Heart Defects, September 10-11, 2012, Atlanta, GA.

21. Leadership for CDC's Safe Medication Use in Pregnancy Initiative Expert Meeting, January 28-29, 2013, Atlanta, GA.
22. Invited presentation: A Public Health Approach to Birth Defects. Seminar Series at University of Georgia, Athens, GA, April 2013.
23. Invited presentation: Congenital Heart Defects: CDC's Role in Surveillance, Research, & Prevention. American Academy of Pediatrics Section on Cardiology and Cardiac Surgery, Orlando, FL, October 25, 2013.
24. Invited presentation: Opportunities and Strategic Directions for Birth Defects Surveillance, Research, & Prevention. National Birth Defects Prevention Network Virtual Meeting, February 26, 2014.
25. Invited presentation: A Overview of CDC's Public Health Research on Spina Bifida. Spina Bifida Association National Conference. June 2014, Anaheim, California.
26. Invited presentation: Public Health Framework for Congenital Heart Defects. Congenital Heart Public Health Consortium Webinar, August 12, 2014.
27. Invited presentation: CDC's Congenital Heart Defects Tracking and Research. CHD Legislative Conference, February 25, 2015.
28. Leadership role: Served on faculty for the 2015 Human Teratogens course sponsored by Harvard Medical School and Massachusetts General Hospital. Boston, MA. April 26-28, 2015.
29. Guest Editor, Special issue of Birth Defects Research Part A: Clinical and Molecular Teratology. National Birth Defects Prevention Study, August 2015, Volume 103, Issue 8, Pages I-V, 649-740.
30. Invited presentation: Progress in birth defects monitoring, research, and prevention in the United States. Beijing, China, September 2015.
31. Invited presentation: CDC Zika Virus Response: Pregnancy and Birth Defects Task Force, CDC Foundation Board, September 20, 2016.
32. Invited presentation: CDC Zika Virus Response: Pregnancy and Birth Defects Task Force, CDC Board of Scientific Counselors, September 27, 2016.
33. Invited presentation: Keynote speaker for the Annual CDC Watsonian Banquet. November 1, 2016, Atlanta, Georgia.
34. Leadership role: Launch of Zika en Embarazadas y Ninos (ZEN) in Barranquilla, Colombia, February 1, 2017.

35. Invited presentation: Zika Virus: Responding to an Emerging Threat to Pregnant Women and Infants. Duke University School of Medicine Grand Rounds, March 27, 2017.
36. Invited presentation: Zika Virus: Protecting Pregnant Women and Babies. American Academy of Pediatrics Webinar, April 11, 2017.
37. Leadership role: Launch of Zika en Embarazadas y Ninos (ZEN) in Cali, Colombia, May 19, 2017.
38. Leadership role: CDC's Zika Virus Response. Transforming Data Into Public Health Action to Protect Moms and Babies. Congressional briefing co-sponsored by Senators Rubio and Nelson and the March of Dimes. July 13, 2017.
39. Leadership role: Launch of Zika en Embarazadas y Ninos (ZEN) in Bucaramanga, Colombia, August 30, 2017.
40. Invited presentation: Emerging threats to pregnant women and infants: Zika and Stopping the Next Zika. Bock Award lecture, Grand Rounds, Alfred I. DuPont Hospital for Children, Wilmington, Delaware, September 27, 2017.
41. Invited presentation: Understanding the Full Impact of Prenatal Opioid Exposure on Infant and Childhood Health, CSTE NAS Working Group Webinar, May 15, 2018.
42. Invited presentations to staff of the House Foreign Affairs Committee and staff of the Florida Congressional Delegation. Data for Action: Update on Babies with Congenital Zika Virus Infection. June 28, 2018.
43. Invited presentations with CDC Foundation to communicate the current gaps in the surveillance of emerging threats to mothers and babies, Fall 2018 through 2019.
44. Invited presentation at Congressional staff briefing: Protecting Mothers and Babies from Emerging Health Threats. April 4, 2019.
45. Invited presentation: Food and Drug Administration meeting on Safety of Asthma Medications during Pregnancy and Lactation. November, 8, 2019.

OTHER PROFESSIONAL ACTIVITIES

- 2019 - Member, Steering Committee, CDC- Georgia Institute of Technology's Tech Research Institute (GTRI) collaboration on innovating surveillance
- 2019 - Member, WHO Zika Roadmap Taskforce
- 2019 - Member, CDC Anthrax Steering Committee
- 2018 - Leadership team for the Council of State and Territorial Epidemiologists (CSTE) working group on neonatal abstinence syndrome
- 2017 - Lead, Cross-CIO Working Group on Surveillance of Emerging Threats to Mothers and Babies
- 2016 -17 Task Force Lead for Pregnancy and Birth Defects in the Emergency Operations Center for CDC's Zika Response.
- 2014 CDC Ebola Response Team, Domestic Field Response Atlanta-based Team Lead for Ohio Field Team (October-November)
- 2014 - Member, Title 42 Scientists Peer Review Board, Centers for Disease Control and Prevention.
- 2012-16 Member, Spina Bifida Association's Professional Advisory Council.
- 2010 - Chairman, Advisory committee for the Vaccines and Medications in Pregnancy Surveillance System. American Academy of Asthma, Allergy, and Immunology.
- 2009 - Ad Hoc Member, FDA's Drug Safety and Risk Management Advisory Committee, Center for Drug Evaluation and Research.
- 2009-10 Epidemiology Team Lead, Maternal Health Team of the Pandemic H1N1 Influenza response
- 2009-10 Member, Environmental Factors Working Group of the International Childhood Cancer Cohort Consortium (I4C)
- 2008-09 Member, Advisory Committee for the Letairis Education and Access Program coordinated by Boston University
- 2006 – Ad hoc consultant, FDA's Joint Meetings of the Dental Products Panel and Peripheral and Central Nervous System Drugs Advisory Committees, Center for Devices and Radiological Health

- 2004 Ad hoc consultant, FDA's Joint Meetings of the Drug Safety & Risk Management and Dermatologic and Ophthalmic Drugs Advisory Committees
- 2003– Member, Society for Epidemiologic Research
- 2003-04 Member, Human Genomics/Acute Public Health response working group
- 2002-04 Member, Medicines and Pharmaceuticals Working Group, National Children's Study Planning
- 2002-04 NCBDDD representative to the Charles C. Shepard Award Committee
- 2000-02 NCEH/NCBDDD representative to the EIS Scientific Program Committee
- 1999-2001 Member, Advisory committee for the Antiretroviral Pregnancy Registry

COMPETITIVE INTRAMURAL FUNDING

- 2019 Funding from the Patient Centered Outcomes Research Trust (\$3.9 million) for the MATernaL and Infant NetworK to Understand Outcomes Associated with Treatment for Opioid Use Disorder during Pregnancy (MAT-LINK).
- 2016-2017 CDC's Zika Response funding: Leadership role in establishing and supervising the U.S. Zika Pregnancy Registry, the Zika Active Pregnancy Surveillance System in Puerto Rico, Proyecto Vigilancia Embarazada de Zika in Colombia, and the ZEN Colombia pregnancy cohort study. Secured approximately \$135 million in federal funding for pregnancy and birth defects surveillance and research activities.
- 2010 CDC's Pandemic Influenza response funding: Leadership role in establishing and supervising the CDC Pregnancy Flu Line to monitor severe influenza in pregnant women (all intensive care unit admissions and all deaths). Obtained approximately \$350,000 funding to continue the CDC Pregnancy Flu Line for the 2010/2011 influenza season.
- 2009 CDC's Pandemic Influenza response funding: Led efforts to obtain approximately \$4.2 million for funding of a Pregnancy Influenza Project to prospectively enroll pregnant women with influenza and monitor their health and that of their fetus/infant through 6 months after delivery.
- 2006 CDC's Office of Genomics and Disease Prevention seed funding: Maternal Smoking, Polymorphisms of Genes Involved with Metabolism of Tobacco Smoke, and Risk for Gastroschisis and Anorectal Atresia/Stenosis in the

National Birth Defects Prevention Study (co-principal investigator); renewed for a 2nd year of funding in 2007.

- 2006 CDC's Director's Discretionary Funding: Contribution of Selected Congenital Infections (Cytomegalovirus, Lymphocytic Choriomeningitis Virus, and Toxoplasma gondii) to the Etiology of Hydrocephalus (co-principal investigator)
- 2005 CDC's Coordinating Center for Health Promotion funding for collaborative projects: Qualitative Assessment of the Attitudes Mothers Have Toward Collecting Biological Specimens on their Infants and Young Children to Study Risk Factors for Birth Defects and Preterm Delivery (co-principal investigator)

AWARDS/HONORS

- 2018 Winner, Service to America Medal for Science and Environment, Partnership for Public Service.
- 2018 Godfrey P. Oakley Jr. Award for significant contributions to the field of birth defects, National Birth Defects Prevention Network
- 2017 Harry Bock Award, Department of Pediatrics, Alfred I. DuPont Hospital for Children
- 2017 65th Annual CDC and ATSDR Honor Awards in the Excellence in Public Health Protection category: Co-leads of Zika Pregnancy and Birth Defects Task Force
- 2017 65th Annual CDC and ATSDR Honor Awards in the Excellence in Epidemiology (International) category: CDC Zika Virus Response, Colombia Team
- 2017 65th Annual CDC and ATSDR Honor Awards in the Excellence in Emergency Response category: Zika Pregnancy and Birth Defects Surveillance Teams
- 2017 65th Annual CDC and ATSDR Honor Awards in the Excellence in Program Delivery (Domestic) category: Zika Pregnancy and Birth Defects Clinical Team
- 2017 Nominated for Charles C. Shepard Award, Assessment & Epidemiology [Birth Defects Among Fetuses and Infants of US Women With Evidence of Possible Zika Virus Infection During Pregnancy.]

- 2016 Outstanding Leadership Award, National Maternal and Child Health Epidemiology Awards by the Coalition for Excellence in MCH Epidemiology
- 2016 Nominated for Charles C. Shepard Award, Assessment & Epidemiology [Specific SSRIs and birth defects: bayesian analysis to interpret new data in the context of previous reports.]
- 2014 Atlanta Federal Executive Board Finalist for Outstanding Supervisor Award
- 2013 Nominated for Charles C. Shepard Award, Data Methods and Study Design [*Modeling the potential public health impact of prepregnancy obesity on adverse fetal and infant outcomes.*]
- 2013 CDC/ATSDR Group Honor Award for Excellence in Surveillance and Health Monitoring (Domestic) for the Critical Congenital Heart Defects Working Group activities in 2012.
- 2012 Nominated for Charles C. Shepard Award, Assessment and Epidemiology [*Influencing clinical practice regarding the use of antiepileptic medications during pregnancy: Modeling the potential impact effects on the prevalences of spina bifida and cleft palate in the United States.*]
- 2012 1st Place Poster Presentation, National Birth Defects Prevention Network, Crystal City, VA.
- 2010 Nominated for Charles C. Shepard Award, Assessment and Epidemiology [*H1N1 2009 influenza virus infection during pregnancy in the USA.*]
- 2010 CDC/ATSDR Group Honor Award for Excellence in Emergency Response for the 2009 H1N1 Maternal Health Team
- 2008 CDC/ATSDR Group Honor Award in Public Health Epidemiology and Laboratory Research for the National Birth Defects Prevention Study Group
- 2004 Charles C. Shepard Science Award for the best CDC manuscript published in 2003 on Assessment and Epidemiology [*Risk of bacterial meningitis in children with cochlear implants.*]
- 2004 2003 Arthur S. Flemming Award (scientific category) for outstanding and meritorious work for the federal government, awarded for contributions to understanding the causes of birth defects, evaluating birth defects prevention activities and assessing health risk in children with birth defects.

- 2004 FDA Commissioner's Special Citation (Meningitis and Cochlear Implant Study Group) for innovative surveillance and investigative efforts in uncovering factors associated with the development of meningitis in pediatric cochlear implant recipients in the United States.
- 2003 CDC/ATSDR Honor Award for Research-Operational for the Cochlear Implant Investigation Team in recognition of a rapid public health response resulting in the reduction of meningitis-related morbidity and mortality associated with cochlear implants in children.
- 2002 Louise Martin Award for a young investigator making outstanding scientific contributions to public health and showing considerable promise for continued success.
- 2002 Nominated for Charles C. Shepard Award, Prevention and Control [*Impact of Folic Acid Fortification of the U.S. Food Supply on the Occurrence of Neural Tube Defects*].
- 2000 Alexander D. Langmuir Memorial Prize for outstanding manuscript on epidemiologic work undertaken while in the Epidemic Intelligence Service (EIS) [*Infantile hypertrophic pyloric stenosis after pertussis prophylaxis with erythromycin: a case review and cohort study*]
- 1999 2nd Prize Poster Presentation, Society for Epidemiologic Research meetings, Baltimore, MD.
- 1992-1994 National Institute of Mental Health Training Grant on Psychosocial and Mental Health Issues and Services for persons with AIDS.
- 1992 Nominated for membership to Iota Chapter of the Delta Omega Society, Honorary Public Health Society.
- 1991 UCLA School of Public Health Alumni Association, Ruth F. Richards, MA, MPH Outstanding Student Award.
- 1991 National Cancer Institute Cancer Training Grant.
- 1985 University of California, Education Abroad Program Participant to the University of Melbourne, Australia.
- 1982 Alumni Scholar, University of California, Riverside.

MENTORSHIP

- 2012—2017 Regina Simeone, MPH, MS, ORISE Fellowship/full-time employee
Served as primary mentor for Ms. Simeone during her ORISE fellowship and then her Associate Service Fellowship focused on congenital heart defects, including key health services research. Ms. Simeone joined the Birth Defects Branch as an Associate Service Fellow in 2013, and as a permanent full-time employees in 2016.
- 2013-2014 Janice Chung, PhD, Prevention Effectiveness Fellow
Mentoring Dr. Chung through CDC's Prevention Effectiveness Fellowship to update and expand the available data on the healthcare costs for major birth defects.
- 2012-2014 Jaynia Anderson, Master's Student in Epidemiology
Rollins School of Public Health, Emory University
Primary mentor for Ms. Anderson for her master's thesis on spina bifida comparing population-based surveillance and clinic-based registries.
- 2011—2013 Elizabeth Ailes, PhD, Epidemic Intelligence Service Officer
Secondary supervisor for Dr. Ailes whose contributions during EIS included assessing implementation of screening for critical congenital heart defects in a state without a specific mandate. Dr. Ailes joined the Birth Defects Branch at the conclusion of EIS and remains on staff.
- 2009—2010 Laura Hartman, MD, ORISE Fellowship
Primary mentor for Dr. Hartman during a one year ORISE fellowship focused on pandemic influenza among pregnancy women, immediately after completing her OB/GYN residency. She provided key clinical assistance on field investigations of severe influenza in pregnancy. Dr. Hartman returned to clinical medicine following the fellowship.
- 2009—2010 Alicia Siston, PhD, Epidemic Intelligence Service Officer
Secondary supervisor for an EIS officer who transferred from a state to a headquarters position in the Influenza Division to assist with the 2009/10 influenza pandemic. She summarized the multi-state occurrence of pandemic influenza among pregnant women in the U.S., and post-EIS joined the health department in Chicago.
- 2007—2012 Candice Y. Johnson, Doctoral Student and Guest Researcher
Mentor and doctoral committee member for Candice Johnson, a doctoral student at Emory University (PhD awarded in 2013). Mentored her in publication of important articles on orofacial clefts and holoprosencephaly, in addition to her doctoral dissertation work on the impact of misclassification of obesity on the observed association between obesity and neural tube defects. Dr. Johnson joined EIS in July 2012.

- 2007—2009 Cheryl S. Broussard, PhD, Epidemic Intelligence Service Officer
Primary supervisor for Dr. Broussard, whose contributions during EIS included a key study on the risk of congenital heart defects and other major birth defects related to use of opioids in early pregnancy. Dr. Broussard remained in the Branch post-EIS and is not the Division Associate Director for Science.
- 2007—2008 Alicia Genisca, Medical Student, CDC Experience Fellowship
Secondary supervisor for Ms. Genisca during her one year fellowship at CDC; primary project was a multi-state descriptive study of the prevalence of orofacial clefts in the National Birth Defects Prevention Study.
- 2006—2009 Sheree Boulet, PhD, ORISE Fellowship
Primary mentor for Dr. Boulet during an ORISE fellowship focused on craniofacial defects and Down syndrome, including key contributions in health services research using the MarketScan data. Dr. Boulet is now on faculty at Emory University.
- 2006—2008 Sarah Collier, MPH, ORISE Fellowship
Secondary mentor for Ms. Collier's ORISE fellowship. She assisted with implementation of a pilot to use residual newborn blood spots to assess the contribution of certain infections to hydrocephalus, and helped coordinate a CDC-convened expert meeting on Down syndrome. Ms. Collier is currently an epidemiologist in NCEZID.
- 2006—2007 Emily Petersen, Medical Student, CDC Experience Fellowship
Secondary supervisor for Ms. Petersen's her CDC Experience Fellowship, with her many outstanding accomplishments including assessing medication sharing among reproductive aged women and an evaluation of the risk statin use in pregnancy. Ms. Petersen returned to the Division for a research month during her OB/GYN residency, joined CDC as an EIS Officer in 2013, served throughout the Zika response on the Pregnancy and Birth Defects Task Force, and is now a medical officer in NCCDPHP.
- 2005—2007 Mahsa Yazdy, MPH, ORISE fellowship
Primary mentor for Ms. Yazdy's ORISE fellowship, which included analyzing the use of special education services by children with orofacial clefts and coordinating two large expert meetings on craniofacial defects. Ms. Yazdy subsequently completed her PhD in Epidemiology at Boston University, and now leads the birth defects program in the Massachusetts Department of Health.
- 2005—2007 Rebecca Bitsko, PhD, Epidemic Intelligence Service Officer
Secondary supervisor for Dr. Bitsko, whose contributions during EIS included an assessment of the association between herbal weight loss

products and birth defects. Dr. Bitsko is a Health Scientist in NCBDDD's Division of Human Development and Disability

- 2005—2006 Jian (Jim) Xing, March of Dimes Fellowship
Primary mentor for work on a National Birth Defects Prevention Network collaborative project: association between preterm birth and birth defects. Mr. Xing is now a mathematical statistician with NCHHSTP.
- 2004—2006 Natalie The, Master's Student, Emory University
Primary mentor for her Master's thesis on risk factors for biliary atresia using data from the National Birth Defects Prevention Study. She enrolled in the doctoral program at the University of North Carolina, Chapel Hill following completion of her Master's degree at Emory.
- 2004—2005 Nataliya Yuskiv, Master's Student, Emory University and March of Dimes Fellowship
Primary mentor for Ms. Yuskiv's thesis project on multivitamin consumption and risk of multiple, major birth defects using data from the Birth Defects Risk Factor Study. During the March of Dimes fellowship, mentored Ms. Yuskiv in her work on a multi-state project to develop the first national prevalence estimates for selected major birth defects in collaboration with the National Birth Defects Prevention Network.
- 2001—2003 Jennita Reefhuis, PhD, Epidemic Intelligence Service Officer
Primary supervisor for Dr. Reefhuis, an outstanding EIS Officer whose accomplishments included winning the Langmuir Prize and Shepard Award for her field investigation (and publication) of bacterial meningitis and cochlear implants. Dr. Reefhuis is now Chief of the Birth Defects Monitoring and Research Branch in NCBDDD.